MODIFIED OLIGOSACCHARIDES

Abstract: Derivatives of sialyl-Lewis X and A, in which the natural neuraminic acid residue and the natural N-acetylglucosamine monomer are replaced.

Description: Modified ohαosaccharides The present invention relates to mimetics of sialyl-Lewis X and A, in which, in the natural tetrasacchaπde, the neuraminic acid residue is replaced by an S-configu rated methyl substituted with one carboxyl residue and one other substituent and the natural N-acetyl group in the N-acetylglucosamine monomer is replaced by a variety of different aliphatic and aromatic substituents or the N-acetylglucosamine residue is replaced by a tetrahydropyran derivative, to processes for the preparation of these compounds, to their use as a pharmaceutical and to pharmaceutical compositions comprising them. The complex process of inflammation, which takes place in several stages, is the body's natural reaction to injuries in which, for example, there is also invasion by infectious agents. Under the influence of cytokines, the endothe uπrwhich lines the blood vessels expresses adhesion proteins on its surface. The P and E selectins bring about, by a protein-carbohydrate interaction with glycolipids and glycoproteins on the leukocyte membrane, the so- called "rolling" of leukocytes. The latter are slowed down by this process, and there is activation of certain proteins (integnns) on their surface which ensure firm adhesion of the leukocytes to the endothe um This is followed by migration of the leukocytes into the damaged tissue. There are many situations in which the recruitment of leukocytes by adhesion to the endo- thelial cells is abnormal and in excess resulting in tissue damage instead of repair. This is the case in disorders such as cardiogenic shock, myocardial infarct, thrombosis, rheumatism, psoriasis, arthritis, dermatitis, acute respiratory distress syndrome, metastatic cancer and transplantation. One of the smallest natural carbohydrate epitopes as ligand for E selectin is sialyl-Lewis X [neuraminic acιd-α(2→3)-D-galactose-β(1 →4)-L-(fucose-α(1 →3))-N-acetyl-D-glucosamιne (sLe * )] Although it has been considered to be potentially useful as an antiinflammatory agent it can only be used as an injectable form as it is orally inactive and has a short half- life in blood Thus, there is a need for compounds which prevent the interaction between P and E selectins and their receptors on the leukocyte membrane and which prevent the initial cellular adhesion process. It has now been found, surprisingly, that simultaneous replacement of the neuraminic acid residue by an S-configu rated methyl substituted with one carboxyl residue and one other substituent and of the natural N-acetyl group in the GlcNAc monomer by a variety of different aliphatic and aromatic substituents or of the GlcNAc residue by a tetrahydropyran derivative results in SLe x mimetics having interesting binding affinity properties. According to the invention there is provided a compound of the formula wherein R is an S-configurated methyl substituted with a carboxy and one other substituent; R 2 is hydrogen, d-C 12 alkyl or C 6 aryl; where the alkyl and the aryl are unsubstituted or substituted by one or more substituents; and Z is a group of the formula Ma, lib or He wherein X is -C(O)-, -C(S)-, -S(O) 2 -, -C(O)Q- or -C(S)Q-, in which Q is NH, O, S, S-C,-C 6 alkylene, NH-C C 6 alkylene or O-d-Cealkylene; R T1 is C,-C 12 alkyl, C 2 -Cι 2 alkenyl, CrCι 2 alkoxy, C 3 -C 12 cycloalkyl, C 3 -Cι 2 cycloalkenyl, Cz-Cnheterocycloalkyl, C 2 -Cuheterocycloalkenyl, C 6 -C 10 aryl, C 6 -C 10 aryloxy, Cs-Cgheteroaryl, C 5 -C 9 heteroaryloxy, C -Cnaralkyl, C 7 -Cnaralkyloxy, C 6 -Cι 0 heteroaralkyl, C 8 -Cnaralkenyl or C 7 -C 10 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents; and R T2 is C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -dιheterocycloalkenyl, C 6 -Cι 0 aryl, C 6 -C 10 aryloxy, C 5 -Cgheteroaryl, C 5 -C heteroaryloxy, C 7 -Cπaralkyl, C 7 -Cι,aralkyl- oxy, C 6 -Cιohθteroaralkyl, C 8 -Cnaralkenyl or C 7 -Ci 0 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents; R B5 is NH 2 , primary amino, secondary amino or amido; R 5 is X'-R T1C , C(O)NR T2C R T3C , C(O)R T4C or C(O)OR T5C , wherein X' is C,-C 4 alkylene, R T1C is hydrogen, halogen, d-C^alkyl, C r Cnheteroalkyl, C 3 -C 12 alkenyl, C 3 -C 12 cycloalkyl, C 3 -Ci 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -, C 10 - or C 14 aryl, C 2 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, Cg-d-aralkenyl, C 8 -C 10 heteroaralkenyl, OR T6C , OC(O)R T4C , SR T4C , SO 2 R T9C or SO 3 R T5C ; each of R T2C , R T3C and R T4C is independently hydrogen, d-C 12 alkyl, d-Cuheteroalkyl, C 3 -C, 2 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -dιheterocycloalkyl, C 2 -dιhetero- cycloalkenyl, C 6 -, C 10 - or d 4 aryl, C 2 -Cgheteroaryl, d-Cuaralkyl, C 6 -C 10 heteroaralkyl, Cg-Ci iaralkenyl or C 8 -Cι 0 heteroaralkenyl; each of R T5C , R 770 and R T8C is independently hydrogen, M y , d-Cι 2 alkyl, d-C n heteroalkyl, C 3 -Cι alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -d 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -dιhetero- cycloalkenyl, C 6 -, C 10 - or C 1d aryl, C 2 -C 9 heteroaryl, C 7 -dιaralkyl, C 6 -C 10 heteroaralkyl, Cg-Cnaralkenyl or C 8 -doheteroaralkenyl; R T6C is hydrogen, d-C 12 alkyl, Cι-dιheteroalkyl, C 3 -Cι 2 alkenyl, C 3 -d 2 cycloalkyl, C 3 -C, 2 cycioalkenyl, CrCiiheterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -, C 10 - or Cι 4 aryl, C 2 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -C 10 heteroaralkyl, Cg-Cnaralkenyl, C 8 -C 0 heteroaralkenyl, SO 3 R T5C , PO 3 R T7C R T8C , C(O)OR T9C , C(S)NR T C R T3C or C(O)NR T2C R T3C ; and R T9C is C C 12 alkyl, C,-dιheteroalkyl, C 3 -C 12 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -Cιιheterocycloalkyl, C 2 -dιheterocycloalkenyl, C 6 -, Cι 0 - or C 4 aryl, C 2 -Cgheteroaryl, Cy-Cπaralkyl, C 6 -Ci 0 heteroaralkyl, C 9 -dιaralkenyl or C 8 -Cιoheteroaralkenyl; wherein the substituent is selected from the group consisting of OH, halogen, NH 2 , C(O)R s2 , C(O)OR s1 , OC(O)R s4 , nitro, cyano, SO 3 H, OSO 3 H, SO 3 M y , OSO 3 M y , NR 20 SO 3 M y , C C 12 alkyl, C 2 -Cι 2 alkenyl, d-C 12 alkoxy, C 3 -C 12 cycloalkyl, C 3 -C 2 cycloalkenyl, C 2 -C 11 heterocycloalkyl, C 2 -C,,heterocycloalkenyl, C 6 -Cι 0 aryl, C 6 -Cιoaryloxy, C 5 -Cgheteroaryl, C 5 -C 9 heteroaryloxy, C -Cnaralkyl, C 7 -Cnaralkyloxy, C 6 -Cι 0 heteroaralkyl, C 8 -Cnaralkenyl, C 7 -C 10 heteroaralkenyl, primary amino, secondary amino, sulfonyl, sulfonamido, carbamido, carbamate, sulfonhydr- azido, carbhydrazido, carbohydroxamic acid and aminocarbonylamido, where R s1 is hydro- gen, M y , C,-Cι 2 alkyl, C 2 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 2 -dιheterocycloalkyl, C 6 -Cι 0 aryl, Cs-Cgheteroaryl, C 7 -Cπaralkyl or C 6 -C 10 heteroaralkyl, R 54 is hydrogen, d-C 12 alkyl, C 2 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 -Cι 0 aryl, C 5 -Cgheteroaryl, C 7 -Cιιaralkyl or C 6 -Cι 0 heteroaralkyl, and R s2 and R 20 are hydrogen, Cι-Cι 2 alkyl, C 2 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cn -heterocycloalkenyl, C 6 -C 10 aryl, C 5 -C 9 heteroaryl, d-Cnaralkyl, C 6 -C 10 heteroaralkyl, C 8 -dι-aralkenyl or C 7 -Cιoheteroaralkenyl, and alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclo- alkyl, heterocycloalkenyl, aryl, aryloxy, heteroaryl, heteroaryloxy, aralkyi, aralkyloxy, hetero- aralkyl, aralkenyl and heteroaralkenyl in turn are unsubstituted or substituted by one of the abovementioned substituents; and y is 1 and M is a monovalent metal or y is 1/2 and M is a divalent metal; and a derivative thereof wherein at least one OH is substituted with SO 3 R T5C , POaR^R™ 0 , C(O)R T9C , C(O)OR T9C , C(S)NR T2C R T3C , C(O)NR T2C R T3C , d-C 12 alkyl, C 3 -C 12 al- keπyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, d-Cnheteroalkyl, C 2 -Cnheterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -, Cio- or C 14 aryl, C 2 -C 9 heteroaryl, C 7 -Cnaralkyl, Ce-CioheteroaralkyI, Cg-daralkenyl or C 8 -Cι 0 heteroaralkenyl; in free form or in salt form. Preferably, Z is bound to the galactose moiety via the carbon atom 4 in case of formula lla and via the carbon atom 3 in case of formulae lib and lie. M is preferably an alkali metal (for example lithium, sodium, potassium, rubidium and caesium), an alkaline earth metal (for example magnesium, calcium and strontium) or manganese, iron, zinc or silver. Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, especially fluorine or chlorine. Alkyl may be linear or branched, preferably branched once or twice in the α position. Examples of alkyl include e.g. methyl, ethyl and the isomers of propyl, butyl, pentyl, hβxyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl, preferably methyl, ethyl, n- and i-propyl, n-, i- and t-butyl. Examples of alkenyl are allyl, but-1 -en-3-yl or -4-yl, pent-3- or 4-en-1-yl or -2-yl, hex-3- or -4- or -5-en-1-yl or -2-yl and (d-C alkyl)CH=CH-CH 2 -. Examples of alkylene are ethylene, 1 ,2-propylene, 1 ,2- or 2,3-butylene, 1 ,2- or 2,3-pentylene, 1 ,2-, 2,3- or 3,4-hexylene. Cycloalkyl and cycloalkenyl may contain 5 to 8, preferably 5 or 6 carbon atoms. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclohexyl. Examples of cycloalkenyl are cyclopropenyl, cyclobutenyl, cyclopent- enyl, cyclohexenyl, cycloheptenyl and cyclooctenyl, preferably cyclohexenyl. Examples of cycloalkylene are 1,2-cyclopropylene, 1 ,2-cyclobutylene, 1 ,2-cyclopentylene, 1,2-cyclo- hexylene, 1 ,2-cycloheptylene and 1 ,2-cyclooctylene. Examples of heterocycloalkylene are pyrroiidinylene, piperidinylene, tetrahydrofuranylene, di- and tetrahydropyranylene. Examples of heterocycloalkyl are derived from pyrrolidine, imidazolidine, oxazolidine, pyrazolidine, piperidine, piperazine and morpholine. Examples of heterocycloalkenyl are derived from 2- and 3-pyrroline, oxazoline, 2- and 4-imidazoline and 2- and 3-pyrazoline. Aryl or heteroaryl is a five- or six-membered ring or a bicycle consisting of two condensed six- or five-membered rings or one six-membered and one five-membered ring, and in the case of heteroaryl one or more C atoms may be replaced, independently of one another, by an atom selected from oxygen, nitrogen and sulfur. Examples are derived from benzene, naphthalene, indene, furan, pyrrole, pyrazole, imidazole, isoxazole, oxazole, furazan, thia- diazole, thiophene, thiazole, oxadiazole, triazole, indole, indazole, purine, benzimidazole, benzoxazole, benzothiazole, pyran, pyridine, pyridazine, triazine, pyrimidine, pyrazine, iso- quinoline, cinnoline, phthalazine, quinoline, quinazoline, pterdine, benzotriazine or quinoxa- line. Aryl is preferably naphthyl and phenyl, particularly phenyl. Heteroaryl is preferably furanyl, pyridinyl and pyrimidinyl. Aralkyi preferably has 7 to 12 C atoms and may be phenyl-C n H 2n - with n equal to a number from 1 to 6. Examples are benzyl, phenylethyl or phenylpropyl. Benzyl and 2-phenylethyl are preferred. Aralkenyl is preferably unsubstituted cinnamyl or cinnamyl ring-substituted by a substituent selected from the group consisting of OH, halogen, COOH, C(O)OM y , d-C 12 alkyl, C,-C 6 alkoxy, C 6 -Cι 0 aryl, SO 3 M y , OSO 3 M y , NR 20 SO 3 M y in which R 20 is as defined above. Heteroaralkyl and heteroaralkenyl are preferably C 4 -C 5 heteroarylmethyl and C 4 -C 5 heteroarylethenyl with one or two hetero atoms from the group of O and N, and the heteroaryl may comprise the abovementioned heteroaryl residues. Alkoxy may be linear or branched, preferably branched once or twice in the α position. Examples of alkoxy include e.g. methoxy, ethoxy and the isomers of propoxy, butoxy, pent- oxy, hexoxy, heptoxy, octoxy, nonoxy, decoxy, undecoxy and dodecoxy, preferred are methoxy and ethoxy. Examples of aryloxy and aralkoxy are phenoxy and benzyloxy. Heteroaryloxy is preferably furanyloxy, pyridinyloxy and pyrimidinyloxy. The primary amino preferably contains 1 to 12, particularly preferably 1 to 6, C atoms, and may be e.g. methyl-, ethyl-, hydroxyethyl-, n- or i-propyl-, n-, i- or t-butyl-, pentyl-, hexyl-, cyclopentyl-, cyclohexyl-, phenyl-, methylphenyl-, benzyl- and methylbenzylamino. The secondary amino preferably contains 2 to 14, particularly preferably 2 to 8, C atoms, and may be e.g. dimethyl-, diethyl-, methylethyl-, di-n-propyl-, di-i-propyl-, di-n-butyl-, diphenyl-, dibenzylamino, morpholino, piperidino and pyrrolidino. Primary amino and secondary ammo preferably correspond to R 8 R 9 N in which each R 8 and R 9 is independently hydrogen, OH, SO 3 M y , OSO 3 M y , Cι-Cι 2 alkyl, C 3 -Cι 2 cycioalkyl, C 2 -Cnheterocycloalkyl, C 6 -C 10 aryl, C 5 -Cgheteroaryl, C -Cnaralkyl, C 6 -C 10 heteroaralkyl, C 8 -d 6 aralkenyl with C 2 -C 6 alkenylene and C 6 -Cιoaryl, or di-Cβ-doaryl-d-Ce-alkyl, which are unsubstituted or substituted by one or more of the above substituents; or R 8 and R 9 together are tetramethylene, pentamethylene, -(CH 2 ) 2 O(CH 2 ) 2 -, -(CH 2 ) 2 S(CH 2 ) 2 - or -(CH 2 ) 2 NR 7 (CH 2 ) 2 -, and R 7 is H, C,-C 6 alkyl, C 7 -Cnaralkyl, C(O)R s2 or sulfonyl. Carbamido, carbamate, carbhydrazido, sulfonamido, sulfonhydrazido and aminocarbonyl- amido preferably correspond to a group R 8 C(O)(NH) p N(R 9 )-, -C(O)(NH) p NR 8 R 9 , R 8 OC(O)(NH) p N(R 9 )-, R 8 R 40 NC(O)(NH) P N(R 9 )-, -OC(O)(NH) p NR 8 R 9 , -N(R 0 )C(O)(NH) P NR 8 R 9 , R B S(O) 2 (NH) p N(R 9 )-; -S(O) 2 (NH) p NR 8 R 9 ; R 8 R 40 NS(O) 2 N(R 9 )-, -NR 40 S(O) 2 NR 8 R 9 or -N(R 0 )C(O)C(O)NR 8 R 9 , in which each of R 8 , R 9 and R 40 is independently hydrogen, OH, C C 12 alkyl, C,-C 12 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -CnheterocycloalkyI, C 2 - Cn heterocycloalkenyl, C 6 -Ci 0 aryl, C 5 -C 9 heteroaryl, C 7 -C 6 aralkyl, C 8 -Cι 6 aralkenyl with C 2 - C 6 alkenylene and C 6 -Cι 0 aryl, C 6 -Cι 5 heteroaralkyl, C 6 -Cι 5 heteroaralkenyl, or di-C 6 -Cι 0 aryl-Cι- C 6 -alkyl; or R 8 and R 9 or R 8 and R 40 in the case of -NR 8 R 9 or R 8 R 40 N- together are tetramethylene, pentamethylene, -(CH 2 ) 2 -O-(CH 2 ) 2 -, -(CH 2 ) 2 -S-(CH 2 ) 2 - or -(CH 2 ) 2 -NR 7 -(CH 2 ) 2 - , and R 7 is H, d-C 6 alkyl, C -d,aralkyl, C(O)R s2 or sulfonyl. The sulfonyl substituent corresponds, for example, to the formula R 10 -SO 2 - in which R 0 is Cι-C 12 alkyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, Ce-doaryl, C 5 -Cgheteroaryl, C T -Cnar- alkyl or C 6 -Cιoheteroaralkyl. The other substituent in R 1 has preferably 1 to 20, more preferably 1 to 16, particularly preferably 1 to 12, and especially preferably 1 to 8 C atoms. The other substituent is preferably selected from the group consisting of unsubstituted and substituted Cι-Cι 2 alkyl, C 2 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cnhetero- cycloalkenyl, Ce-Cioaryl, C 5 -C 9 heteroaryl, C 7 -dιaralkyl, Ce-Cioheteroaralkyl, C 8 -Cnaralkenyl and C 7 -C 10 heteroaralkenyl. The other substituent is particularly substituted methyl, or 2-sub- stituted ethyl or unsubstituted cyclohexyl. Examples of suitable substituents are the substituents mentioned above in the definition of R 2 , especially OH, halogen (F, CI or Br), carboxyl, -SO 3 H, C(O)OM y , SO 3 M y , OSO 3 y , NR 20 SO 3 M y in which R 20 is as defined above, or d-C 12 alkyl, Cι-Cι 2 alkoxy, nitro, -NH 2 , primary amino with 1 to 20 C atoms, secondary amino with 2 to 30 C atoms, cyano, C 3 -C 8 cycloalkyl, C 3 -C 6 heterocycloalkyl, C 6 -C 10 aryl, C 3 -C 9 heteroaryl, C 7 -d 6 heteroaralkyl, where the hetero atoms are selected from the group of O, S and N atoms, and carbamide, carbamate, carbhydrazide, sulfonamide, sulfonhydr- azide or aminocarbonylamide, whose N atoms are unsubstituted or substituted by a hydrocarbon group or hydroxy-hydrocarbon group with 1 to 20 C atoms. The hydrocarbon groups and heterohydrocarbon groups in turn are unsubstituted or substituted, for example with C,-C 6 alkyl, C C 6 alkoxy, carboxyl, halogen (F, CI or Br), -OH, -CN or -NO 2 . In a particular embodiment of the compounds of the formula I, R corresponds to a group of the formula II, in which R 3 is hydrogen or M y ; and R 4 is Cι-Cι 2 alkyl, C 2 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cn heterocycloalkenyl, C 6 -Cιoaryl, Cs-Cgheteroaryl, C -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, C 8 -Cnaralkenyl or C 7 -C 10 heteroar- alkenyl, which are unsubstituted or substituted by one or more substituents selected from the abovementioned group of substituents. Preferred compounds of the formula I are those in which R 1 corresponds to a group of the formula II in which R 3 is hydrogen or M y and R 4 is (a) unsubstituted d-d 2 alkyl; Cι-C 12 alkyl which is substituted by one or more substituents selected from the group consisting of -NH 2 , primary amino, secondary amino, Cι-Cι 2 sul- fonyl, carbamide, carbamate, carbhydrazide, sulfonamide, sulfonhydrazide, ammo- carbonylamido, C 3 -Cι 2 cycloalkyl, CrC β alkoxy, phenyloxy and benzyloxy; unsubstituted C 3 -Cι 2 cycloalkyl; C 3 -C 12 cycloalkyl which is substituted by one or more substituents selected from the group consisting of d-C 6 alkyl, d-C 6 alkoxy, d-C 12 sulfonyl, phenyloxy and benzyloxy; Ce-doaryl; C 3 -C 9 heteroaryl with 1 or 2 hetero atoms selected from oxygen and nitrogen; C 7 -Cι 6 aralkyl with d-C 6 alkyl and C 6 -C 10 aryl; C -Cι 6 heteroaralkyl with d-C 6 alkyl and C 3 - Cioheteroaryl with 1 or 2 hetero atoms selected from oxygen and nitrogen and a total of 3 to 5 carbon atoms; or such C 6 -Cι 0 aryl, C 3 -C 9 heteroaryl, C 7 -d 6 aralkyl and C 3 -d 6 heteroaralkyl which are substituted by one or more substituents selected from the group consisting of OH, halogen, Cι-C 12 sulfonyl, carboxyl, C(O)OM y , d-Cι 2 alkyl, Cι-C 6 alkoxy, C 6 -Cι 0 aryl, SO 3 M y , OSO 3 y , NR 20 SO 3 M y in which R 20 , y and M are as defined above; or (b) d-Ci.alkyl, C 3 -Cι 2 cycloalkyl or C 7 -Cnaralkyl, in particular CH 2 -C 6 H 5 and (CH 2 ) 2 -C 6 H 5 , which are unsubstituted or substituted by one or more substituents selected from the abovementioned group of substituents. More preferred are those compounds in which the substituent for R 4 is selected from the group consisting of NH 2l C 3 -d 2 cycloalkyl, primary amino, secondary amino, sulfonamido, carbamido and aminocarbonylamido. Particularly preferred substituents for d-Cι 2 alkyl are NH 2 , cyclohexyl, C 6 -C,oaryl, R 8 R 9 N-, R 8 C(O)N(R 9 )-, R 8 S(O) 2 N(R 9 )-, R 8 NHC(O)NR 9 - and NR 9 C(O)NHR 8 in which R 8 , R 9 , R 8 and R 9 are as defined above. Particularly preferred compounds within this group are those in which R 4 is R' 4 , R' 4 being CHrC 6 H 5 , (CH 2 ) 2 -C 6 H 5 , cyclohexyl, methyl, ethyl or isopropyl which are unsubstituted or substituted by one or more substituents selected from the group consisting of NH 2 , cyclohexyl, Ce-Cioaryl, R 8 C(O)N(R 9 )-, R 8 S(O) 2 N(R 9 )-, R β NHC(O)NR 9 -, NR 9 C(O)NHR 8 and R 8 R 9 N-, in which each R 8 , R 9 , R 8 and R 9 is independently hydrogen, Cι-Cι 2 alkyl, C 3 -Cι cycloalkyl, C 6 -Cι 0 aryl or C 7 -Cnaralkyl, which are unsubstituted or substituted by one or more substituents selected from the group consisting of OH, halogen, C(O)OM y , nitro, cyano, SO 3 M y , OSO 3 M y , NHSO 3 M y , Cι-C 12 alkyl, Cι-C 12 alkoxy and C 6 -C 10 aryl, where y and M are as defined above Particularly preferred compounds are those in which each R 8 , R 9 , R 8 and R 9 is independently hydrogen, Cι-Cι 2 alkyl, cyclohexyl, phenyl, naphthyl or C 7 -Cnaralkyl, which are unsubstituted or substituted by one or more substituents selected from the group consisting of OH, F, CI, C(O)ONa, nitro, cyano, SO 3 Na, Cι-C 6 alkyl, methoxy and phenyl. In a preferred group of compounds of the formula I, R 1 corresponds to formula II, in which R 4 is R" 4 , R" 4 being C β Hu, CH(CH 3 ) 2) CH 2 -phenyl, (CH 2 ) 2 -phenyl, CH 2 NHC(O)-phenyl, CH 2 NHC(O)(CH 2 ) 3 -phenyl, CH 2 NHC(O)(CH 2 ) 3 OH, CH 2 NHC(O)CF 3 , CHaNHCfOJCeH,,, CH 2 NHC(O)C,ιH 23 , CH 2 NHC(O)CH(C 6 H 5 ) 2 , CH 2 HNC(O)NHC 6 H 5 , CH 2 NHC(O)C 2 H 4 CO 2 Na, CH 2 NHC(O)C 6 [(1 ,3,4,5)OH] 4 H 7 , CH 2 NHC(O)C 6 H 4 -p-SO 3 Na, CH 2 NHC(O)C 6 H 4 CI, CH 2 C β H„ f (CH 2 ) 2 C 6 Hιι, CH 2 NH 2l CH 2 NHC(O)C 6 H 4 NO 2 , CH 2 NHC(O)C 6 H 4 OCH 3 , CH 2 NHC(O)C 10 H 7 , CH 2 NHC(O)C 6 H 4 (3,4)CI 2 , CH 2 NHC(O)C 6 H 4 CH 3 , CH 2 NHC(O)C 6 H 4 C 6 H 5 , CH 2 NHC(O)C 6 H 4 CN, CH 2 NHC(O)C 6 H 4 COONa, CH 2 NHC(O)(CHOH) 2 COONa, CH 2 N[CH 2 CH(CH 3 ) 2 ][C(O)-phenyl], CH 2 N(CH 2 CH=CH-phenyl)[C(O)-phenyl], CH 2 N[C(O)C 6 H 5 ]CH 2 C 6 H 5 , CH 2 NHCH 2 -phenyl, CH 2 N[C(O)C 6 H 5 ](CH 2 ) 3 C 6 H 5 , CH 2 NHCH 2 CH=CH-phenyl, CH 2 NHCH 2 CH(CH 3 ) 2 , CH 2 N(CH 2 -phenyl) 2 , CH 2 N[CH 2 CH(CH 3 ) 2 ] 2 , CH 2 NHSO 2 -p-nitrophenyl, CH 2 NHSO 2 -p-tolyl, CH 2 NHSO 2 CF 3 , CH 2 NHC(O)NHC 6 H 5 or CH 2 N[SO 2 -p-nitrophenyl][CH 2 CH(CH 3 ) 2 ] 2 . A preferred group of compounds of the formula I are those in which R 2 is hydrogen, unsubstituted or substituted C C 6 alkyl, preferably d-C 4 alkyl, especially methyl or ethyl, wherein the substituent is selected from C(O)OH, -C(O)ONa, -C(O)OK, -OH, -C(O)-NR 8" R 9" and -S0 2 -NR B R 9 , in which R 8" is H, d-C 4 alkyl, C 2 -C 4 hydroxyalkyl, phenyl or benzyl, and R 9" independently has the meaning of R 8 , or R 8 and R 9 are together tetramethylene, pentamethylene or -CH 2 CH 2 -0-CH 2 CH 2 -. Particularly preferred compounds are those in which R 2 is hydrogen, methyl, ethyl, HO(O)CCH 2 CH 2 -, NaOC(O)CH 2 CH 2 - or R 8 " R 9" NC(0)CH 2 CH 2 -, and R 8 and R 9 are, independently of one another, H, CrC 6 alkyl, C 2 -C 4 hydroxyalkyl, phenyl, benzyl or, together, morpholino. A first preferred embodiment of the invention comprises the compounds of formula IA in which X, R 1 , R 2 , R T1 and R T2 have the above meanings. Q in X is preferably NH, O or S. X is preferably -C(O)-, -C(S)-, -C(O)O- or -C(S)O-, more preferably -C(O)- or -C(O)O-. A preferred embodiment of the invention are those compounds of the formula IA wherein R T is d-C 12 alkyl, which is unsubstituted or substituted by one or more substituents selected from the group consisting of OH, halogen, C(O)OR s1 , OCfOJR 54 , CfOJR 82 , nitro, NH 2 , cyano, SO 3 M y , OSO 3 M y , NR 20 SO 3 M y , where R s1 , R 84 , R 52 , R 20 , y and M are as defined above. A more preferred embodiment of the invention are those compounds of the formula IA wherein R T1 is Cι-Cι 2 alkyl, which is unsubstituted or substituted by one or more, preferably one C(O)OR s1 , where R sl is as defined above. Most preferably R T1 is Cι-Cι 2 alkyl, which is substituted by C(O)OCι-Cι 2 alkyl or C(O)ONa. A specially preferred meaning of R T1 is (CH 2 ) 8 C(O)OCH 3 or (CH 2 ) β C(O)ONa. A preferred embodiment of the invention are those compounds of the formula IA wherein R T2 is C 3 -C, 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 -Cι 0 aryl or C 5 -Cgheteroaryl, which are unsubstituted or substituted by one or more substituents selected from the group consisting of OH, halogen, nitro, NH 2 , cyano, C Cι 2 alkyl, C 2 -Cι 2 alkenyl, Cι-Cι 2 alkoxy, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -C 10 aryl, C 6 -Cι 0 aryl- oxy, C 5 -C 9 heteroaryl, C 5 -C heteroaryloxy, C 7 -dιaralkyl, C 7 -Cι aralkyloxy, C 6 -C 10 heteroar- alkyl, C B -Cι ,aralkenyl, C 7 -Cι 0 heteroaralkenyl. More preferred are those compounds of the formula IA wherein R T2 is C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 -Cι 0 aryl or Cs-Cgheteroaryl, which are unsubstituted or substituted by one or more substituents selected from the group consisting of OH, d-Cι 2 alkyl, C 6 -Cι 0 aryl or Cs-Cgheteroaryl. Most preferred meanings of R τz are -3,5-(OH) 2 C 6 H 3 , -3,4-(OH) 2 C 6 H 3 , -3,4-(OCH 3 ) 2 C 6 H 3 , -2-(OH)C 6 H 4 and thyminyl, especially preferred are -3,4-(OH) 2 C 6 H 3 and -3,4-(OCH 3 ) 2 C 6 H 3 . A particularly preferred embodiment of the invention comprises compounds of the formula laA wherein X, R 3 , R 4 , R T1 and R T2 are as defined above. Preferred compounds of the formula laA are those in which X is -C(O)-, -C(S)-, -S(O) 2 -, -C(O)Q- or -C(S)Q-, in which Q is NH, O or S; R 3 is hydrogen or M y ; R 4 is C 7 -Cnaralkyl, C 3 -Cι 2 cycloalkyl or Cι-C 12 alkyl, which is unsubstituted or substituted by one or more substituents selected from the group consisting of NH 2 , C 3 -Cι 2 cycloalkyl, primary amino, secondary ammo, sulfonamido, carbamido and aminocarbonylamido; R T1 is Cι-Cι 2 alkyl, which is unsubstituted or substituted by one or more substituents selected from the group consisting of OH, halogen, C(O)OR s1 , OC(O)R s4 , C(O)R s2 , nitro, NH 2 , cyano, SO 3 My, OSO 3 M y , NR 20 SO 3 M y , where R s1 , R 84 , R s2 , R 20 , y and M are as defined above; and R T2 is C 3 -C, 2 cyclo- alkyl, C 2 -C n heterocycloalkyl, C 6 -Cι 0 aryl or C 5 -Cgheteroaryl, which are unsubstituted or substituted by one or more substituents selected from the group consisting of OH, halogen, nitro, NH 2 , cyano, Cι-C, 2 alkyl, C 2 -C 12 alkenyl, Cι-C 12 alkoxy, C 3 -Cι 2 cycloalkyl, C 3 -C 12 cyclo- alkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -Cι 0 aryl, C 6 -Cιoaryloxy, C 5 -Cgheteroaryl, C 5 -Cgheteroaryloxy, Crd.aralkyl, C7-C1 aralkyloxy, C 6 -C 10 heteroaralkyl, Cβ-Cnaralkenyl and C 7 -Cιoheteroaralkenyl. More preferred compounds of the formula laA are those in which X is -C(O)-, -C(S)-, -C(O)O- or -C(S)O-; R 3 is hydrogen or M y where y and M are as defined above; R 4 is CH 2 -C 6 H 5 , (CH 2 ) 2 -C 6 H 5 , cyclohexyl, methyl, ethyl or isopropyl which are unsubstituted or substituted by one or more substituents selected from the group consisting of NH 2 , C 3 -C 12 cycloalkyl, primary amino, secondary amino, sulfonamido, carbamido and aminocarbonylamido; R T1 is d-Cι 2 alkyl, which is unsubstituted or substituted by one or more C(O)OR s \ where R s1 is as defined above; and R T2 is C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocyclo- alkyl, C 6 -Cι 0 aryl or C 5 -C 9 heteroaryl, which are unsubstituted or substituted by one or more substituents selected from the group consisting of OH, Cι-C 12 alkyl, C 6 -C 10 aryl or C 5 -C 9 heteroaryl. Most preferred compounds of the formula laA are those in which X is -C(O)- or -C(O)O-; R 3 is hydrogen or M y where y and M are as defined above; R 4 is R' 4 ; R T1 is C Cι 2 alkyl, which is substituted by C(O)OR s1 , where R s1 is as defined above; and R T2 is -3,5-(OH) 2 C 6 H 3 , -3,4-(OH) 2 C 6 H 3l -3,4-(OCH 3 ) 2 C 6 H 3 , -2-(OH)C 6 H 4 or thyminyl. Especially preferred compounds of the formula laA are those in which X is -C(O)- or -C(O)O-; R 3 is hydrogen or M y ; R 4 is CH 2 -C 6 H 5 , (CH 2 ) 2 -C 6 H 5 , cyclohexyl, methyl, ethyl or iso- propyl which are unsubstituted or substituted by one or more substituents selected from the group consisting of NH 2 , cyclohexyl, C 6 -C 10 aryl, R 8 C(O)N(R 9 )-, R 8 S(O) 2 N(R 9 )-, R 8 NHC(O)NR 9 -, NR 9 C(O)NHR 8 and R 8 R 9 N-, in which R 8 , R 9 , R 8' and R 9' are, independently of one another, hydrogen, Cι-C 12 alkyl, cyclohexyl, phenyl, naphthyl or C 7 -Cnaralkyl, which are unsubstituted or substituted by one or more substituents selected from the group consisting of OH, F, CI, C(O)ONa, nitro, cyano, SO 3 Na, d-C 6 alkyl, methoxy and phenyl; R T1 is C,-C, 2 alkyl, which is substituted by C(O)OC,-C 12 alkyl; and R T2 is -3,4-(OH) 2 C 6 H 3 and -3,4-(OCH 3 ) 2 C 6 H 3 . Among these compounds of the formula laA those are preferred wherein X is -C(O)- or - -CC((OO))OO--;; RR 33 iiss hhyyddrogen, K or Na; R 4 is R" 4 ; R T1 is CH 3 ; and R T2 is -3,4-(OH) 2 C 6 H 3 or -3,4-(OCH 3 ) 2 C 6 H 3 . A second preferred embodiment of the present invention relates to compounds of the formula IB (IB) in which R 2 , R 3 , R 4 and R B5 have the above meanings. In a particular embodiment of the compounds of the formula IB, R B5 corresponds to a group of the formula llaB or HbB -NR B6 R B7 (llaB), C |bB ) in which R B6 is hydrogen, d-Cι 2 alkyl, C 3 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -d 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -C heterocycloalkenyl, C 6 - or Cι 0 aryl, C 5 -C 9 heteroaryl, C 7 -C,ιar- alkyl, C 6 -Cι 0 heteroaralkyl, Cg-Cnaralkenyl or C 8 -C 10 heteroaralkenyl; R B7 is C,-Cι 2 alkyl, C 3 -C 12 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocyclo- alkyl, C 2 -C heterocycloalkenyl, C 6 - or Cι 0 aryl, C 5 -Cgheteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 hetero- aralkyl, C 9 -C,,aralkenyl, C 8 -Cι 0 heteroaralkenyl, C(O)OR s1 , CfOJR 88 , SO 2 R 10 or SO 3 M y , wherein R B8 is hydrogen, C(O)OR s1 , Cι-Cι 2 alkyl, C 3 -Cι 2 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C, 2 cycloalkenyl, C 2 -C,ιheterocycloalkyl, C 2 -C heterocycloalkenyl, C 6 - or C 10 aryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, C 9 -Cnaralkenyl, C 8 -Cιoheteroaralkenyl, primary ammo or secondary amino; R s1 , R 10 , y and M are as defined above; and R B11 is C 2 -C 4 alkylene, C 2 -C 4 alkenylene, 1 ,2-C 3 -Cι 2 cycloalkylene, 1 ,2-C 3 -C 12 cycloalkenylene, 1 ,2-C 2 -Cnheterocycloalkylene, 1 ,2-C 2 -Cnheterocycloalkenylene, 1 ,2-C 6 - or Cioarylene, 1 ,2-C 5 -C 9 heteroarylene, 1 ,2-C 8 -Cnaralkylene or 1 ,2-C 6 -Cιoheteroaralkylene; and alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, aralkyi, heteroaralkyi, aralkenyl and heteroaralkenyl are unsubstituted or substituted by one or more substituents selected from the abovementioned group of substituents. Preferred compounds of the formula IB are those in which R 3 is H, K or Na. Preferred compounds of the formula IB are those compounds in which R 4 is R 4 b, R b being Cι-C, 2 alkyl, C 3 -Cι 2 cycloalkyl or C 2 -Cn heterocycloalkyl, where alkyl, cycloalkyl and heterocycloalkyl are unsubstituted or substituted by one or more substituents as defined above, preferably R 4 is optionally substituted Cι-C 6 alkyl, more preferably methyl substituted by C 3 -Cι 2 cycloalkyl. Particularly preferred compounds of the formula IB are those compounds in which R 4 is cyclohexyl-methyl. In a particular embodiment of the invention R B5 is primary amino or amido, preferably amido. Preferably R B5 corresponds to a group of the formula llaB or HbB, in which R 86 is hydrogen, Cι-C 12 alkyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 - or Cioaryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl or C 6 -Cι 0 heteroaralkyl; R B7 is d-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl, C 2 -Cn heterocycloalkyl, C 6 - or C 10 aryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, C(O)OR' s1 , C(O)R B8 , SO 2 R 10 or SOaMy, wherein R 0 , y and M are as defined above, R' s1 is M y , Cι-Cι 2 alkyl, C 3 -C 12 cycloalkyl, C 2 -Cn heterocycloalkyl, C 6 - or C 10 aryl, C 5 -C 9 heteroaryl, C 7 -C,, aralkyi or C 6 -Cιoheteroaralkyl; R 88 is hydrogen, C(O)OR s1 , Cι-Cι 2 alkyl, C 3 -d 2 cycloalkyl, C 2 -dιhetero- cycloalkyl, C 6 - or Cioaryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, primary amino or secondary amino; and R B11 is C 2 -C alkylene, 1 ,2-C 3 -d 2 cycloalkylene or 1 ,2-C 6 - or C 10 arylene; and alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyi and heteroaralkyi are unsubstituted or substituted by one or more substituents as defined above. Preferably R B5 corresponds to a group of the formula llaB or llbB, in which R 86 is hydrogen, Cι-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl or C 6 - or Cioaryl; R B7 is Cι-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl, C 6 - or Cι 0 aryl, C(0)OR ,,sl , C(O)R ,B8 , SO 2 R' 10 or SO 3 M y , wherein R" s1 is M y , Cι-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl or C 6 - or C, 0 aryl; R' 88 is hydrogen, C(O)OR" s ', Cι-C, 2 alkyl, C 3 -Cι 2 cycloalkyl or C 6 - or Cι 0 aryl, primary amino or secondary amino; R' 10 is d-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl or C 6 - or Cioaryl; and R B " is 1 ,2-C 6 - or Cioarylene; and alkyl, cycloalkyl and aryl are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, nitro, d- Cι 2 alkyl, d-Cι 2 alkoxy, C 3 -C 12 cycloalkyl or C 6 - or Cioaryl; and M y is K or Na. More preferably R B5 corresponds to a group of the formula llaB, in which R 86 is hydrogen, d-Cι 2 alkyl, C 3 - C, 2 cycloalkyl or C 6 - or Cioaryl; R B7 is d-C^alkyl, C 3 -Cι 2 cycloalkyl, C 6 - or Cioaryl, C(O)OR" s1 , C(O)R ,BS , SO 2 R' 10 or SO 3 M y , wherein R" sl , R ,B8 , R ,1 °, y and M are as defined above; and alkyl, cycloalkyl and aryl are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, nitro, Cι-Cι 2 alkyl, d-Cι 2 alkoxy, C 3 -Cι 2 cycloalkyl or C 6 - or Cioaryl. Most preferably R 85 corresponds to a group of the formula llaB, in which R 86 is hydrogen or Cι-Cι 2 alkyl; R B7 is Crd 2 alkyl, C(O)Od-Cι 2 alkyl, CfOJR 88 , SO 2 C 6 - or Cioaryl or SO 3 M y ; R 88 is C(O)OM y , d-C 12 alkyl, C 3 -C 12 cycloalkyl, C 6 - or Cioaryl or primary amino; and alkyl, cycloalkyl and aryl are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, nitro, Cι-Cι 2 alkyl, d-Cι 2 alkoxy or C 6 - or Cioaryl. Especially preferred compounds are those in which R 85 corresponds to a group of the formula llaB, in which R 86 is hydrogen, methyl or benzyl; R 87 is methyl, benzyl, C(O)OR s1a , C(O)R B8a , SO 2 R 10a or SO 3 Na, wherein R s1a is methyl or methyl substituted with one or more substituents selected from phenyl, phenyl substituted with one or more substituents selected from methoxy and nitro, and naphthyl; R 88 * is C(O)ONa, methyl substituted with one or more phenyl, ethyl substituted with phenyl, cyclohexyl, phenyl, phenyl substituted with one or more substituents selected from methoxy, chlorine, nitro, phenyl and tπfluormethyl, naphthyl, NH(CH 2 ) 2 COONa, NHC 6 H 5 or NHCH 2 CH 3 ; and R 10a is tolyl. Most preferably R B5 is R ,B5 , R' 85 being -NHC(O)CH 2 C 6 H 5 , -NHC(O)CH(C 6 H 5 ) 2 , -NHSO 3 Na, -NHC(O)(CH 2 ) 2 C 6 H 5 , -NHC(O)C 6 Hn, -NHC(O)C 6 H 5 , -NHC(O)C 6 H 4 (4-OCH 3 ), -NHCH 2 C 6 H S , -NHC(O)C 6 H 3 (3,4-OCH 3 ) 2 , -NHC(O)C 6 H 4 (4-CI), -NHC(O)C 6 H 4 (4-NO 2 ), -NHC(O)C 6 H 4 (4-C 6 H 5 ), -NHC(O)C 6 H 4 (4-CF 3 ), -NHC(O)COONa, -NHC(O)-2-naphthyl, -NHC(O)-1 -naphthyl, -NHC(O)NH(CH 2 ) 2 COONa, -NHC(O)NHC 6 H 5 , -NHC(O)NHCH 2 CH 3 ; -NHC(O)OCH 2 C 6 H 5l -NHC(O)OCH 2 C 6 H 2 (4,5-OCH 3 ) 2 (2-NO 2 ), -NHC(O)OCH 2 C 6 H 4 (4-NO 2 ), -NHSO 2 C 6 H 4 (4-CH 3 ), -NHC(O)OCH 2 -2-naphthyl, -NHCH 3 , -N(CH 2 C 6 H 5 ) 2 , -N(CH3)C(O)C 6 H 5 , -N(CH 2 C 6 H 5 )C(O)C 6 H 5 or -phthalimido. Especially preferred as R B5 are -NHC(O)CH(C 6 H 5 ) 2 , -NHC(O)C 6 Hn, -NHC(O)C 6 H 4 (4-C 6 Hs), -NHC(O)C 6 H 5 , -NHC(O)C 6 H 4 (4-OCH 3 ), -NHC(O)C 6 H 3 (3,4-OCH 3 ) 2 , -NHC(O)C 6 H 4 (4-CI), -NHC(0)C 6 H 4 (4-NO 2 ), -NHC(O)-2-naphthyl, -NHC(O)NHC 6 H 5 , -NHC(O)OCH 2 C 6 H 5 , -NHSO 3 Na, -NHCH 2 C 6 H 5 or -N(CH 2 C 6 H 5 ) 2 . A particularly preferred embodiment of the invention comprises compounds of the formula laB in which R 3 is hydrogen or M y and R 85 is a group of formula llaB or HbB as defined above. Preferred compounds of the formula laB are those in which R 3 is H, K or Na; R 06 is hydrogen, Cι-C 12 alkyl, C 3 -d 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 - or Cι 0 aryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl or C 6 -Cι 0 heteroaralkyl; R 87 is Cι-d 2 alkyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocyclo- alkyl, C 6 - or Cioaryl, C 5 -Cgheteroaryl, C 7 -C,,aralkyl, C 6 -C, 0 heteroaralkyl, C(O)OR s1 , C(O)R 88 , SO 2 R 10 or SO 3 M yι wherein R' s1 , R 10 , y and M are as defined above; R 88 is hydrogen, C(O)OR' s1 , Cι-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 - or Cioaryl, Cs-Cgheteroaryl, C 7 -Cιιaralkyl, C 6 -Cι 0 heteroaralkyl, primary amino or secondary amino; and R B11 is C 2 -C 4 alkylene, 1 ,2-C 3 -Cι 2 cycloalkylene or 1 ,2-C 6 - or Cι 0 arylene; and alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyi and heteroaralkyi are unsubstituted or substituted by one or more substituents as defined above. More preferred compounds of the formula laB are those in which R 3 is H, K or Na; R 86 is hydrogen, Cι-C 12 alkyl, C 3 -Cι 2 cycloalkyl or C 6 - or Cioaryl; R B7 is Cι-C 12 alkyl, C 3 -d 2 cycloalkyl, C 6 - or doaryl, C(O)OR" s1 , C(O)R ,B8 , SO 2 R' 10 or SO 3 M y , wherein R' ,s1 , R' 88 , R ,1 °, y and M are as defined above; and R 811 is 1 ,2-C 6 - or Cι 0 arylene; and alkyl, cycloalkyl and aryl are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, nitro, Cι-C 12 alkyl, Cι-C 12 alkoxy, C 3 -Cι 2 cycloalkyl or C 6 - or C 10 aryl. Most preferred compounds of the formula laB are those in which R 3 is H, K or Na; R 86 is hydrogen, d-C, .alkyl, C 3 -Cι 2 cycloalkyl or C 6 - or Cioaryl; R 87 is Cι-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl, C 6 - or doaryl, C(O)OR" s1 , C(O)R ,B8 , SO 2 R' 10 or SO 3 M y , wherein R" s1 , R ,B8 , R' 10 , y and M are as defined above; and alkyl, cycloalkyl and aryl are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, nitro, Cι-C 12 alkyl, C,-Cι 2 alkoxy, C 3 -Cι 2 cycloalkyl or C 6 - or Cioaryl. Especially preferred compounds of the formula laB are those in which R 3 is H, K or Na; R 86 is hydrogen or d-C^alkyl; R 87 is Cι-Cι 2 alkyl, C(O)Od-Cι 2 alkyl, CfOJR 88 , SO 2 C 6 - or Cioaryl or SO 3 M y , wherein R 88 is C(O)OM y , Cι-Cι 2 alkyl, C 3 -Cι 2 cycloalkyl, C 6 - or Cioaryl or primary am o; and alkyl, cycloalkyl and aryl are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, nitro, Cι-Cι 2 alkyl, Cι-C 12 alkoxy or C 6 - or Cι 0 aryl. Especially preferred compounds of the formula laB are those in which R 3 is H, K or Na; R E is hydrogen, methy /Il oorr bbeennzzyyll;; RR 8877 iiss methyl, benzyl, C(O)OR s1a , C(O)R B8a , SO 2 R 10a or SO 3 Na, wherein R s1a , R 883 and R ,0a are as defined above. A third preferred embodiment of the present invention relates to compounds of the formula IC in which R ,2 , r Rι3 , R ri" and R have the above meanings. Preferred compounds of the formula IC are those in which R 3 is H, K or Na. Preferred compounds of the formula IC are those compounds in which R is R as defined above. In a particular embodiment of the invention R 5 is X'-R T1C , C(O)NR T2C R T3C or C(O)OR T5C , wherein X' is C,-C 4 alkylene and R T1C , R T C , R T C and R T5C are as defined above. Preferably R 5 is X'-R T1C or C(O)OR T5C , wherein X', R τ,c and R T5C are as defined above. More preferred are compounds of the formula IC wherein R 5 is X'-R T1Ca or C(O)OR T5C , wherein X' and R T5C are as defined above and R T1Ca is hydrogen or OR T6C wherein R T6C is as defined above. Most preferred are compounds of the formula IC wherein R 5 is X'-R T1C or C(O)OR T5C , wherein X' is Cι-C 4 alkylene, R T1C is hydrogen or OH; and R T5C is hydrogen or M y . Preferably R 5 is CH 2 OH, CH 3 or C(O)ONa. Particularly preferred compounds of the formula IC are compounds of the formula laC in which R 3 is hydrogen, K or Na; and R 5 is X'-R T1C , C(O)NR T2C R T3C or C(O)OR T5C , wherein X', R T1C , R T2C , R T3C and R T5C are as defined above. More preferred are compounds of the formula laC wherein R 3 is hydrogen, K or Na; and R 5 is X'-R T1Ca or C(O)OR T5Ca , wherein X', R T1Ca and R T5C are as defined above. Most preferred are compounds of the formula laC wherein R 3 is hydrogen, K or Na; and R 5 is X'-R τ,c or C(O)OR TSC , wherein X' is C,-C 4 alkylene, R T1C is hydrogen or OH; and R T5C is hydrogen or M y . More preferably R 5 is CH 2 OH, CH 3 or C(O)ONa. The present invention also comprises a process for the preparation of the compounds of the formula I wherein the corresponding galactose-GlcNAc-disaccharide or galactose-tetra- hydropyran dimer is linked with the corresponding fucose-derivative or the corresponding fucose-GlcNAc-disaccharide or fucose-tetrahydropyran dimer is linked with the corresponding galactose, wherein the groups R 1 , R T1 , X-R T2 , R 85 and or R 5 are optionally introduced before or after the formation of the dimer or trimer. Where required, one or more protecting groups are removed and the compounds thus obtained are converted into salts. In a preferred process for the preparation of the compounds of the formula IA the corresponding galactose-GlcNAc-disaccharide is linked with the corresponding fucose-derivative or the corresponding fucose-GlcNAc-disaccharide is linked with the corresponding galactose wherein the groups R 1 , R T1 and X-R T2 are optionally introduced before or after the formation of the dimer or trimer. Typically the process for the preparation of the compounds of the formula IA comprises (A1 ) reacting a compound of the formula IIIA wherein each R 12 independently is hydrogen or a protecting group, R 60 is R 1 or a protecting group and R 15 is a leaving group, with a compound of the formula IVA wherein R 12 is as defined above, R 61 is R T1 or a protecting group, or OR 61 is R 15 , R 62 is hydrogen, a protecting group or X-R T2 , R 63 is hydrogen or a protecting group and R 64 is hydrogen or a protecting group or R 12 and R 64 together form a protecting group, and (A2) reacting the resulting disaccharide with a compound of the formula VA wherein R 2 , R 12 and R 5 are as defined above; wherein the groups R 1 , R T1 and X-R T2 are optionally introduced before or after step (A1 ) or step (A2); and, where required, removing the protecting groups; or (B1 ) reacting a compound of the formula VA with a compound of the formula IVA, and (B2) reacting the resulting disaccharide with a compound of the formula IIIA; wherein the groups R 1 , R T1 and X-R T2 are optionally introduced before or after step (B1 ) or step (B2); and, where required, removing the protecting groups. For example, a compound of formula ia may be prepared by reacting a compound of formula IVA with R T, -OH, followed by a reaction with a compound of formula VA. The resulting compound is reacted with R T2 -X-R 14 , wherein R 14 is a leaving group, then with a compound of formula IIIA and finally with R 1 -R 13 , wherein R 13 is a leaving group. Where required, the protecting groups are removed and the compounds of formula IA are converted into salts. As it will be appreciated, this reaction scheme is an example and may be carried out in a different sequence to produce a compound of formula IA. The compounds of the formula IIIA, IVA and VA are known or may be obtained in accordance with methods known and practiced in the art. Hydroxy protecting groups are generally known in the sugar and nucleotide chemistry and are described, for example, by Greene and Wuts [Protective Groups in Organic Synthesis, Wiley, New York (1991 )]. Examples of such protecting groups are: linear and branched Cι-C θ alkyl, in particular d-C alkyl, for example methyl, ethyl, n- and i-propyl, n-, i- and t-butyl; benzyl, methylbenzyl, dimethylbenzyl, methoxybenzyl, dimethoxybenzyl, bromo- benzyl, 2,4-dιchlorobenzyl; diphenylmethyl, di(methylphenyl)methyl, di(dimethylphenyl)- methyl, dι(methoxyphenyl)methyl, di(dιmethoxyphenyl)methyl, tnphenylmethyl, trιs-4,4',4"- tert-butylphenylmethyl, di-p-anisylphenylmethyl, trι(methylphenyl)methyl, tri(dιmethylphenyl)- methyl, methoxyphenyl(dιphenyl)methyl, di(methoxyphenyl)phenylmethyl, trι(methoxy- phenyl)methyl, trι(dιmethoxyphenyl)methyl; triphenylsilyl, alkyldiphenylsilyl, dialkylphenylsilyl and tπalkylsilyl with 1 to 20, preferably 1 to 12, and particularly preferably 1 to 8 C atoms in the alkyl groups, for example triethylsilyl, tπ-n-propylsilyl, i-propyl-dimethylsilyl, t-butyl-di- methylsilyl, t-butyl-diphenylsilyl, n-octyl-dimethylsilyl, (1 ,1 ,2,2-tetramethylethyl)dιmethylsilyl; C 2 -Cι 2 -, in particular C 2 -C 8 acyl, such as acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, benzoyl, methylbenzoyl, methoxybenzoyl, chlorobenzoyl and bromobenzoyl; substituted methy dene groups which are obtainable by acetal or ketal formation from adjacent hydroxyl groups of the sugars or sugar derivatives with aldehydes and ketones, which preferably contain 2 to 12 or 3 to 12 C atoms, for example d-C^alkylidene, preferably Cι-C 6 alkylιdene and in particular C,-C 4 alkylidene, such as ethylidene, 1 ,1- and 2,2-propyl- idene, 1 ,1 - and 2,2-butylιdene, benzylidene. The protecting groups may be identical or different. Preferably R 12 and R 64 together form an alkylidene group with, preferably 1 to 12 and, more preferably 1 to 8 C atoms. These protecting groups may be removed under neutral or weak- ly acidic conditions. R 12 and R 64 are, particularly, together alkylidene, for example unsubstituted or alkyl- or alkoxy- substituted benzylidene. Compounds of the formula IB wherein R 85 is a group of formula llaB may be produced by reacting a compound of the formula IVB wherein R 2 and R 4 have the abovementioned meanings (a) in the case where R 86 is hydrogen and (a1 ) R B7 is C,-C 12 alkyl, C 3 -C 12 alkenyl, C 7 -C 11 aralkyl, C 6 -C 10 heteroaralkyl, C 8 -C^aralkenyl, C 8 -C 10 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents, with an aldehyde of formula VB R B7 CHO (VB) wherein R B7 is hydrogen, 0,-0, ..alkyl, C 2 -C 11 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -C, heterocycloalkyl, C 2 -C 11 heterocycloalkenyl, C 7 -C 10 aralkyl, C 6 - or C 10 aryl, C 6 -C 9 heteroaralkyl, C 5 -C 9 heteroaryl, C 8 -C 10 aralkenyl or C 7 -C 9 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents; or (a2) R B7 is d j -C^alkyl, C 3 -C 12 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -O, 1 hetero- cycloalkyl, C 2 -C„heterocycloalkenyl, C 7 -C aralkyi, C 6 -C 10 heteroaralkyl, C 8 -C^aralkenyl, C 8 -C 10 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents, with a ketone of formula VlaB or VlbB R Br COR Br" (VlaB) o=(^ R B1 (VlbB) wherein each of R 87 and R B independently is d-Cnalkyl, C 2 -Cnalkenyl, C 3 -C 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cn heterocycloalkyl, C 2 -Cn heterocycloalkenyl, C 7 -Cι 0 aralkyl, C 6 - or Cι 0 aryl, C 6 -C 9 heteroaralkyl, C 5 -C 9 heteroaryl, C 8 -Cιoaralkenyl, which are unsubstituted or substituted by one or more substituents; and R B12 is C 3 -C 10 alkylene or C 3 -Cι 0 alkenylene, for example cyclobutanon, cyclodecanon, cyclobutenon and cyclodecen- on, which are unsubstituted or substituted by one or more substituents; or (a3) R B7 is C(O)OR s1 , CfOJR 88 or SO 2 R 10 , wherein R s1 and R 10 are as defined above and R 88 is hydrogen, C(O)OR s1 , Cι-Cι 2 alkyl, C 3 -Cι 2 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C 2 cycloalkenyl, C 2 -C heterocycloalkyl, C 2 -Cι heterocycloalkenyl, C 6 - or Cioaryl, C 3 -C 9 heteroaryl, d-Cπar- alkyl, C 6 -Cι 0 heteroaralkyl, Cg-Cnaralkenyl or C 8 -Cι 0 heteroaralkenyl; and alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, aralkyi, heteroaralkyi, aralkenyl and heteroaralkenyl are unsubstituted or substituted by one or more substituents, with a compound of formula VIIB R 3 R B7" (VIIB) wherein R B7" is C(O)OR s1 , CfOJR 88 or SO 2 R 10 , wherein R s1 , R 88 and R 0 are as defined above; and R 13 is a leaving group; or (a4) R B7 is C(O)R 88 , wherein R 88 is primary amino or secondary amino; with an isocyanate OCNR 8 (VIIIB) wherein R B is hydrogen, SO 2 R 10 , OSO 2 R 10 , d-Cι 2 alkyl, C 3 -C, 2 cycloalkyl, C 2 -C,, heterocycloalkyl, C 6 - or Cioaryl, C 5 -C 9 heteroaryl, C 7 -Cn aralkyi, C 6 -C 10 heteroaralkyl, C 8 -Cι 6 aralkenyl, which are unsubstituted or substituted by one or more substituents; (a5) R B7 is SO 3 M y , wherein M y has the abovementioned meanings, with a complex of formula IXB SO 3 • NC 5 H 5 (IXB); (b) in the case where R 86 is C Cι 2 alkyl, C 3 -Cι 2 alkenyl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, Cg-Cnaralkenyl or C 8 -Cι 0 heteroaralkenyl; and (b1 ) R B7 is C,-C 12 alkyl, C 3 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnhetβro- cycloalkyl, C 2 -Cnheterocycloalkenyl,C 7 -C,ιaralkyl, C 6 -Cι 0 heteroaralkyl, Cg-Cnaralkenyl or C 8 -Cι 0 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents subsequently with an aldehyde of formula VB or a ketone of formula VlaB or VlbB; (b2) R 87 is C(O)OR s , CfOJR 88 or SO 2 R 10 , wherein R s1 is hydrogen, M y , C,-C, 2 alkyl, C 3 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 - or Cioaryl, C 5 -Cgheteroaryl, C 7 -C aralkyl or C 6 -Cι 0 heteroaralkyl; R 88 is hydrogen, C(O)OR s1 , C Cι 2 alkyl, C 3 -Cι 2 alkenyl, C 3 -C 12 cyctoalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 - or Cι 0 aryl, C 5 -C 9 heteroaryl, C -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, C 9 -Cnaralkenyl or Cβ-doheteroaralkenyl; R 10 is C,-Cι 2 alkyl, C 3 -C 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 - or Cioaryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl or C 6 -C 0 heteroaralkyl, which are unsubstituted or substituted by one or more substituents; subsequently with an aldehyde of formula VB and a compound of formula VIIB; or (b3) R 87 is CfOJR 88 , wherein R 88 is primary amino or secondary amino; subsequently with an aldehyde of formula VB and a compound of formula VIIIB; (b4) R 87 is SO 3 M y , subsequently with an aldehyde of formula VB and a compound of formula IXB. Compounds of formula IB wherein R 85 is a group of formula llaB wherein R 87 is C 6 - or C 10 aryl or C 5 -Cgheteroaryl, may be produced by reductively aminating a compound of formula IVbB wherein R 2 , R 3 and R 4 are as defined above and R 12 is hydrogen or a protecting group with an aromatic amme, optionally removing the protecting groups, and further reacting the resulting compound as described in (b) above. Compounds of formula IB wherein R 85 is a group of formula llbB may be produced by reacting a compound of the formula IVB wherein R 2 , R 3 and R 4 are as defined above with a compound of formula VllbB (VllbB) wherein R has the abovementioned meanings; and each R 13 is independently a leaving group. Leaving groups may be: halides, such as chloride, bromide and iodide, and oates for example of the formula R 8r -O ' (in which case formula VIIB is an anhydride R Br -O-R B ) or alkoxides (alkylO ). The compounds of the formula VB to IXB are known or may be obtained by known methods. The compounds of the formula IVB and IVbB are novel and form part of the present invention. They may be obtained starting from commercially available 3,4,6-triacetoxyglucal by (a) deprotecting said compound, protecting its 6-position, coupling with a suitably protected and activated galactose, replacing the 6-protecting group by a leaving group, substituting with an N-nucleophile, coupling with a suitably protected and activated L-fucose, introducing the group -CH(COOR B8 )R 4 , in which R 88 is a carboxylate protecting group and R 4 has the abovementioned meanings, into the prior deprotected galactose residue, reducing the glucal residue, removing the fucose protecting groups and optionally reducing the residue R 4 ; or (b) reducing said compound, deprotecting and converting the 6-position into a leaving group, coupling with a suitably protected and activated galactose, coupling with a suitably protected and activated L-fucose, substituting the 6-posιtιon with an N-nucleophile, introducing the group -CH(COOR 88 )R 4 into the prior deprotected galactose residue and removing the protecting groups; or (c) reducing said compound, deprotecting and protecting its 4- and 6-posιtιon, coupling with a suitably protected and activated galactose, removing the 4- and 6-protectιng groups, converting the 6-posιtιon into a leaving group, substituting with an N-nucleophile, coupling with a suitably protected and activated L-fucose, introducing the group -CH(COOR B8 )R 4 into the prior deprotected galactose residue, reducing the glucal residue and removing the fucose protecting groups; or (d) deprotecting said compound, converting the 6-position into a leaving group, substituting with an N-nucleophile, coupling with a suitably protected and activated galactose, coupling with a suitably protected and activated L-fucose, introducing the group -CHfCOOR 88 ^ 4 into the prior deprotected galactose residue, reducing the glucal residue, removing the fucose protecting groups and optionally reducing the residue R 4 ; or (e) deprotecting said compound, protecting its 6-position, coupling with a suitably protected and activated galactose, reducing the glucal double bond, converting the 6-position into a leaving group, substituting with an N-nucleophile, coupling with a suitably protected and activated L-fucose, introducing the group -CHfCOOR 88 ^ 4 into the prior deprotected galactose residue, reducing the glucal residue and removing the fucose protecting groups; or (f) deprotecting said compound, protecting its 6-positιon, coupling with a suitably protected and activated galactose and subsequently with a suitably protected and activated L-fucose, introducing the group -CH(COOR B8 )R 4 into the prior deprotected galactose residue, protecting the remaining galactose hydroxy groups, deprotecting the 6-protectιng group of the glucal and oxidizing said position. The abovementioned strategies (a) to (e) may for example be performed by using a suitably protected and activated galactose which already contains the group -CH(COOR B8 )R 4 . This compound may for example be obtained starting from an activated galactose by introducing a protecting group at the anomenc position, deprotecting said compound, introducing the group -CH(COOR B8 )R 4 protecting the residual hydroxyl groups, deprotecting and activating the anomenc position. Suitable activating groups for sugars and glycosylation are known to the person skilled in the art and are described for example by Toshima and Tatsuta [Chem. Rev. 93:1503 (1993)], Paulsen [Angew. Chem. Int. Ed. Engl. 21 :155 (1982)] and Schmidt and Kmzy [Adv. Carbohydr. Chem Biochem. 50:21 (1994)]. Examples for N-nucleophiles are NaN 3 , NH 3 , primary amines and secondary amines, preferably the N-nucleophile is NaN 3 . Suitable reducing conditions are for example H 2 , Pd/C 10%, MeOH; H 2 , Pd(OH) 2 /C 10%, dioxane/water 2/1 ; or H 2 , Rh/AI 2 O 3 5%, dioxane/water 2/1. The compounds of formula IVB, IVbB and VB, VIB, VIIB, VIIIB and IXB respectively may be employed in equimolar amounts or, advantageously, in excess, for example in an amount which is up to 5 times, preferably 2 times the amount of the compound of formula IVB or IVbB Examples of carboxylate protective groups are esters, preferably methyl and benzyl esters Methyl esters are preferably cleaved under the abovementioned basic conditions and benzyl esters are preferably cleaved under the abovementioned reducing conditions. Compounds of formula IC may be prepared by converting a compound of the formula IIC wherein R 2 and R 4 have the abovementioned meanings, R 3 has the meanings of R 3 or is a protecting group and R 12 means a protecting group applying procedures known in the art. Examples of such conversions are e.g. (A) in the case that R 5 is X'-R T1C , wherein X' is methylene and R T1C is (a) hydrogen: removing the alcohol functionality; (b) halogen: transforming the alcohol function into a halide function; (c) C,-Cι 2 alkyl, d-Cnheteroalkyl, C 3 -d 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -d 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -dιheterocycloalkenyl, C 6 -, Cι 0 - or Cι 4 aryl, C 2 -C 9 heteroaryl, C 7 -Cιιaralkyl, C 6 -Cι 0 heteroaralkyl, C 9 -Cnaralkenyl or C 8 -Cι 0 heteroaralkenyl: oxidizing the alcohol, reacting the resulting aldehyde with a suitable C-nucleophile and removing the resulting secondary alcohol functionality; (d) OR T6C , wherein R T6C is (α) hydrogen: removing the protecting groups; (β) CrCι 2 alkyl, d-Cnheteroalkyl, C 3 -C 12 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cι, heterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -. Cι 0 - or Cι aryl, C 2 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Ci 0 heteroaralkyl, Cg-Cnaralkenyl or C 8 -Cιoheteroaralkenyl: forming the corresponding ether; (γ) SO 3 R T5C or PO 3 R T7C R T8C : introducing the SO 4 - or PO 4 -function using a suitable SO 3 - or PO 3 -donor (eg. SO 3 • pyridme); (δ) C(O)OR T9C : reacting with a compound of formula Hal-C(O)-OR T9C ; (ε) C(S)NR T C R T3C or C(O)NR T2C R T3C : reacting with for example phosgene [C(O)CI 2 ] or thiophosgene [C(S)CI 2 ], and substituting the resulting carbonic/thiocarbonic acid chloride with HNR T2C R T3C ; (e) OC(O)R T4C : forming the corresponding ester; (f) SR T4C , SO 2 R T9C or SO 3 R T5C : transforming the alcohol group into a leaving group, reacting with a suitable S-nucleophile and optionally oxidizing the resulting SR group; (B) in the case that R 5 is X'-R T1C , wherein X' is C 2 -C 4 alkylene: proceeding as in (A(c)) followed by one of the procedural variants A(a) to A(f); (C) in the case that R 5 is C(O)NR T2C R T3C : oxidizing the alcohol and reacting the resulting carboxyiic acid to form the corresponding amide; (D) in the case that R 5 is C(O)R T4C- oxidizing the alcohol and optionally reacting the resulting aldehyde with a suitable C-nucleophile and oxidizing the resulting secondary alcohol functionality to the corresponding ketone; (E) in the case that R 5 is C(O)OR T5C : oxidizing the alcohol and optionally reacting the resulting carboxyiic acid to form the corresponding ester; wherein each of the above variants (except of [A(d)(α)]) is followed by the removal of the protecting groups The compounds of the formula IIC are new and form part of the present invention. They may be produced by linking the corresponding galactose-1 ,2-dιdeoxyglucose-dιsaccharιde with the corresponding fucose-derivative or the corresponding fucose-1 ,2-dιdeoxyglucose- disacchaπde with the corresponding galactose wherein the group -CH(COOR 3 )R 4 is optionally introduced before or after the formation of the dimer or trimer. The compounds of formula IIC may be obtained by following a procedure as disclosed for the compounds of formula IA above, the group -CH(COOR 3 )R 4 being introduced by reaction with R 13 -CH(COOR 3 )R 4 . Leaving groups as R 13 may be a halide or unsubstituted or halogenated R-SO 2 -, in which R is Cι-Cι 2 alkyl, in particular d-C 6 alkyl and mono-, di- or trifluoromethyl, C 5 -C 6 cycloalkyl, phenyl, benzyl, Cι-Cι 2 alkylphenyl, in particular Cι-C alkylphenyl, nitrophenyl, or Cι-Cι 2 alkyl- benzyl, in particular d-C 4 alkylbenzyl, for example methane, ethane, propane, butane, benzene, benzyl- and p-methylbenzenesulfonyl. Preferred leaving groups are CI, Br, I, -SO 2 CF 3 (triflate) and p-nitrobenzenesulfonyl, -SO 2 CF 3 being more preferred. Leaving groups in the meaning of R 4 are for example halides, such as preferably chloride and bromide, and especially in the case when X is -C(O)- carboxylates and groups of for example the formulae where,n Examples of leaving groups which are especially useful in glycosylation reactions, i.e. here in the meaning of R 15 are -S-CH 3 , -S-CH 2 -CH 3 , -S-Ph, -O-C(=NH)-CCI 3 , -O-C(-O)-CH 3 , OP(OR) 2 and halogen for example CI, Br and I. These leaving groups can be in the axial or in the equatorial position. It has proved advantageous to activate the 3-OH group of the galactose residue prior to etheπfication by stannylation. Particularly suitable for this purpose are dialkylt oxides, dialkyltin alkoxylates and bιs(trιalkyl)tιn oxides. Some examples are dibutyltin oxide, dibutyl- tιn(O-methyl) 2 and (trιbutyltιn) 2 O. The activating agents are preferably used in stoichiometπc amounts. In this case, the reaction is carried out in two stages, namely a) activation and b) coupling with e.g. R T1 -OH. Further details of the preparation of the compounds of the formula IA, IB and IC are described e.g. in the examples. The compounds of formula I exhibit valuable pharmacological properties as indicated in tests and are therefore indicated for therapy. In particular the compounds of formula I inhibit the binding of E-selectin to SLe a as disclosed in Example C1 and the interaction of E- selectin and its natural ligand as disclosed in Example C2. The compounds are accordingly indicated for preventing or treating conditions or diseases which are mediated by the binding of selectin in cellular adhesion, e.g. acute or chronic inflammatory or autoimmune diseases such as rheumatoid arthritis, asthma, allergy conditions, psoriasis, contact dermatitis, adult respiratory distress syndrome, inflammatory bowel disease and ophthalmic inflammatory diseases, infection diseases such as septic shock, traumatic shock, thrombosis and inappropriate platelet aggregation conditions, cardiovascular diseases such as heart attacks, reperfusion injury, multiple sclerosis and neoplastic diseases including metastasis conditions, strokes and acute or chronic rejection of organ or tissue transplants. Acute and chronic rejection play a role in the transplantation of organs or tissues from a donor to a recipient of the same species (allograft) or different species (xenograft). Among such transplanted organs or tissues and given illustratively are heart, lung, combined heart- lung, trachea, liver, kidney, spleen, pancreatic (complete or partial, e.g. Langerhans islets), skin, bowel, or cornea or a combination of any of the foregoing. For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired, In general, however, satisfactory results are achieved at dosage rates of from 0.1 to about 100 mg/kg/day, administered in 1 , 2, 3, or 4 doses/day, or in sustained release form. Suitable daily dosages for oral administration to larger mammals, e.g., humans, are generally about 50 to 1500 mg, preferably in the order of from 200 to 800 mg. Unit dosage forms suitably comprise from about 25 mg to 0.750 g of a compound of the invention, together with a pharmaceutical acceptable diluent or carrier therefor. The compounds of formula I may be administered by any conventional route of administration, e.g. enterally, preferably orally, e.g. in the form of tablets or capsules, or par- enterally e.g. in form of injectable solutions or suspensions. Pharmaceutically acceptable salts are to be understood as meaning, in particular, the alkali metal and alkaline earth metal salts, for example sodium, potassium, magnesium and calcium salts. Sodium and potassium ions and their salts are preferred. In accordance with the foregoing the present invention further provides: (a) a compound of formula I or a pharmaceutically acceptable salt thereof for use as a pharmaceutical; (b) a method for preventing or treating disorders as indicated above in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; (c) a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable diluent or carrier; (d) a compound of formula I or a pharmaceutically acceptable salt thereof for use in the manufacturing of a medicament for use in the method as in (b) above. The compound may be administered alone or in combination with one or more other anti-inflammatory or immunosuppressive agents, for example in combination with cyclosporin A and analogs thereof, FK-506 and analogs thereof, rapamycin and analogs thereof, myco- phenolic acid, mycophenolate mofetil, mizoribine, 15-deoxyspergualine, leflunomide, steroids, cyclophosphamide, azathioprene (AZA), or anti-lymphocyte antibodies or immuno- toxins such as monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, or CD25; especially in combination with a T-cell suppressant, e.g., cyclosporin A or FK-506. Such combination therapy is further comprised within the scope of the invention, e.g., a method according to 1 above further comprising administration concomitantly or in sequence of a therapeutically or synergistically effective amount of such a second immunosuppressive or anti-inflammatory agent. The following examples are offered as a way for illustration of this invention and not in a way of limitation. Abbreviations used are: Ac: Acetyl; Bz: Benzoyl; Bn: Benzyl; Ph: Phenyl; SEt: C 2 H 5 S; HRP: Horse radish peroxid- ase; BSA: Bovine serum albumin; DMTST: Dimethyl(methylthio)sulfonium triflate; OTf: Tri- flate; THG: Thioglycerol; THF: Tetrahydrofuran; NBA: m-Nitrobenzyl alcohol; DMF: N,N-Di- methylformamide; DME: 1 ,2-Dimethoxyethane; MeOH: Methanol; PAA: Polyacryl amide; SA: Streptavidin; TBDMS: tert.butyldimethylsilyl; PTSA: p-toluene sulfonic acid; RT: room temperature; MW: molecular weight; MS: mass spectroscopy; FAB: Fast atom bombardment mass spectroscopy. An unconnected hyphen in the formulae means methyl. A: Preparation of starting compounds Example A1b: Preparation of compound No. A1b HO a) 2 (3.74 g, 14 mmol) prepared according to Kinzy and Schmidt, Tetrahedron Lett. 28:1981-1984 (1987) and imidate 3 [Rio et al., Carbohyd. Res. 219:71-90 (1991)] (12.76 g, 17 mmol) are dissolved in dry CH 2 CI 2 (100 ml) under argon at 0°C. 100 μl (1.8 mmol) of a solution of triethylsilyltriflate (117 μi in 2 ml CH 2 CI 2 ) are added. After 4 h the reaction mixture is treated with NEt 3 (0.5 ml) and evaporated. Purification by repeated flash chromatography on silica (ethyl acetate/- hexane = 1/3) affords 4 as a white solid. b) 4 (740 mg, 0.88 mmol) is dissolved in 120 ml THF/pyridine 1/1 in a plastic container. At 0°C HF-pyridine complex 70/30 (20 ml) is added. After 2 h sat. NaHCO 3 solution is added and the mixture is extracted with ethyl acetate. The organic layer is washed with sat. NH 4 CI dried with MgSO 4 and evaporated. Purification by flash chromatography on silica (ethyl acetate/hexane = 1/1 ) gives 6 which is used directly in the next step. c) A solution of 6 (1.145 mg, 1.15 mmol), para-tolouenesulfonyl chloride (361 mg, 1 .89 mmol) and dry pyridine (10 ml) in dry CH 2 CI 2 (100 ml) is heated under reflux for 7 d. The reaction mixture is evaporated and purified by flash chromatography on silica (ethyl acetate/hexane = 2/3) to give in the order of elution 7 and recovered starting material. d) A solution of 7 (855 mg, 0.97 mmol) and NaN 3 (253 mg, 3.89 mmol) in dry DMF (10 ml) is stirred for 16 h. The reaction mixture is extracted with ethyl acetate, the organic layer is washed with water, dried with MgSO 4 , evaporated and purified by flash chromatography on silica (ethyl acetate/petrol ether = 1/2) to give 8. e) 8 (50 mg, 0.066 mmol) and imidate 9 [Wegmann and Schmidt, Carbohyd. Res. 184:254-261 (1988)] (58 mg, 0.100 mmol) are dissolved in ether (5 ml) under argon. 50 μl (0.05 eq.) of a solution of triethylsilyltriflate (60 μl in 4 ml ether) are added. After 15 min the reaction mixture is treated with NEt 3 , evaporated and purified by repeated flash chromatography on silica (ethyl acetate/hexane = 1/2) and subsequently by gel filtration on sephadex LH20 eluting with MeOH to give 10. f) A solution of 10 (160 mg, 0.137 mmol) in degassed MeOH (10 ml) is treated with a catalytic amount of NaOMe solution. After 3 h the reaction mixture is neutralized with crushed Amberlyst 15, filtered over hyflo, evaporated and purified by flash chromatography on silica (chloroform/isopropanol = 8/1 ) to give 11. g) 11 (1.17 g, 1.56 mmol) and dibutyltinoxide (Bu 2 SnO) (388 mg, 1.56 mmol) are suspended in MeOH under argon and refluxed for 2 h. The resulting clear solution is evaporated. The vacuum of the rotatory evaporator is released by flushing with argon not with air. The residue is once evaporated with benzene and dried on high vacuum. Dried CsF (1.18 g, 7.8 mmol) is added under argon to the resulting residue and subsequently a solution of (fl)-benzyl-3-phenyl-2-trifluoromethanesulfonyloxypropionate 12 [Degerbeck et al., J. Chem. Soc. Perkin Trans. 1 :1 1 -14 (1993)] (3.0 g, 7.8 mmol) in DME (50 ml). After stirring for 18 h at room temperature the mixture is diluted with ethyl acetate and washed with sat. KH 2 PO 4 and water, dried with MgSO and purified by flash chromatography on silica (ethyl acetate/hexane = 2/1) to give 13. BnO h) A mixture of 13 (902 mg, 0.91 mmol) dissolved in MeOH/H 2 O/AcOH 50/50/1 (30.3 ml) and Pd/C 10% (1 g) is stirred under H 2 (balloon) for 50 h. Some ml of CH 2 CI 2 are added. The mixture is filtered over hyflo, evaporated, dissolved in water and freeze dried. The resulting residue (527 mg) is purified by P2 gelfiltration eluting with water to give 14. i) A mixture of 14 (361 mg, 0.60 mmol) dissolved in H 2 O/dioxane 3/2 (45 ml) and Rh 5%/AI 2 O 3 (180 mg) is stirred under H 2 (balloon) for 2 d. The mixture is filtered over hyflo, evaporated, dissolved in water and purified by P2 gelfiltration eluting with water to give after freeze drying pure A1b and an impure sample of A1b as white foams. C 27 H 47 NO, 4 (MW=609.67): MS (FAB positive mode, THG) 632 (M+Na), 610 (M+H). 1 H NMR (500 MHz, D 2 O) δ 4.85 (d, 1 H, Fuel ), 4.62 (q, 1H, Fuc5), 4.46 (d, 1 H, Gall), 4.05-3.96 (m, 2H), 3.94- 3.89 ( , 1 H), 3.85 (d, 1 H, Gal4), 3.82 (dd, 1 H, Fuc3), 3.76-3.72 (m, 2H), 3.70-3.64 (m, 2H), 3.61 -3.50 (m, 4H), 3.50-3.39 (m, 2H), 3.34 (dd, 1 H, Gal3), 3.14 (dd, 1 H), 2.21-2.16 (m, 1 H), 1.78-1.71 (m, 1 H), 1.68-1.44 (m, 8H), 1.22-1.08 (m, 6H, including at 1.15 (d, Fuc6)), 0.94- 0.80 (m, 2H). Example A1c: Preparation of compound No. A1c a) A mixture of 1 c (1.00 g, 3.18 mmol) and dibutyltinoxide (1.38 g; 5.57 mmol, 1.75 eq) in 50 ml of dry methanol is heated under reflux for 2 h in an argon atmosphere. The solvent is removed and the residue dried in high vacuo for 16 h. The colorless oil is dissolved in 50 ml of abs. dimethoxyethane. Under argon, 2c (2.82 g, 9.54 mmol, 3.0 eq) (2C) and dry cesiumfluoride (1.21 g, 7.95 mmol, 2.5 eq) are added and the resulting suspension stirred at RT for 6 h. Then, 200 ml of a 1 N KH 2 PO 4 solution containig 2 g of potassium- fluoride is added followed by the extraction with chloroform (3 x 175 ml). The combined organic layers are washed with brine (2 x 200 ml) and the solvent is removed. Flash chromatography on silica gel (toluene/ethylacetate 5:1) gives 3c as a colorless oil. b) To a solution of 3c (2.00 g, 4.03 mmol) in 18 ml of abs. pyridine benzoylchloride (2.8 ml, 24.1 mmol, 3.0 eq) and 4-(dimethylamino)-pyridine (0.147 g, 1.2 mmol, 0.3 eq) are added at 0°C. The mixture is stirred at RT for 16 h. Ethylacetate (300 ml) is added followed by the extraction with 0.1 N HCI (5 x 100 ml), sat. NaHCO 3 solution (5 x 100 ml) and brine (2 x 100 ml). The organic layer is dried with Na 2 SO 4 , the solvent is removed and the residue is subjected to flash chromatography on silica gel (hexane/ethylacetate 4:1-→2:1). Compound 4c is isolated as a colorless solid. c) A suspension of 5c (4.00 g, 27.0 mmol) 6c (9.12 ml, 53.6 mmol) / _. OMe MeO— <^ >— < (6c) OMe and PTSA (0.60 g) in 150 ml abs. acetonitrile is stirred at RT for 2 h. After the addition of 1.5 g solid NaHCO 3 the solvent is removed and the residue is subjected to flash chromatography on silica gel (toluene/ethylacetate 2:1→1:1 ). Compound 7c is isolated as a colorless foam. d) A suspension of 4c (1.00 g, 1.42 mmol), 7c (0.756 g, 2.84 mmol, 2.0 eq) and molecular sieves (3 A, 1.0 g) in abs. CH 2 CI 2 (5 ml) is stirred for 2 h under argon. Within 1 h a solution of 8c (0.55 g, 2.13 mmol, 1.5 eq) [Garegg, P.E., Carbohydrate Research 149:69 (1986)] in abs. CH 2 CI 2 (4 ml) is added drop- wise at RT and the mixture is stirred for 1 h. Then, 50 ml of a sat. NaHCO 3 solution are added, the layers are separated and the aquous layer is extracted with CH 2 CI 2 (2 x 25 ml). The combined organic layers are dried with Na 2 SO 4 , the solvent is removed and the residue is dissolved in a mixture of CH 2 CI 2 (50 ml) and methanol (10 ml). Camphersulfonic acid (50 mg) is added and the mixture is stirred for 2 h at RT. The solvents are removed and the residue is subjected to flash chromatography on silica gel (toluene/ethylacetate 2:1 ). Compound 9c is isolated as a colorless oil. e) A solution of 9c (847 mmg, 0.821 mmol) and triphenylmethyl chloride (343 mg, 1.23 mmol, 1.5 eq) in abs. pyridine (18 ml) is stirred under argon for 24h at 70°C. Then, additional triphenylmethyl chloride (171 mg, 0.615 mmol, 0.75 eq) is added and stirring continued for 24 h. The solvent is removed in vacuo and the residue purified by flash chromatography on silica gel (toluene/ethylacetate 8:1→5:1 ) to yield 10c as a colorless foam. f) A suspension of 10c (1000 mg, 0.969 mmol), tetraethylammonium bromide (405 mg, 1.94 mmol, 2.0 eq) and molecular sieves (3A, 1.2 g) in abs. CH 2 CI 2 (4.5 ml) and abs. DMF (4.5 ml) is stirred under Argon for 2 h at RT (suspension A). In a separate reaction flask a solution of bromine (357 mg, 2.23 mmol, 2.3 eq) in abs. CH 2 CI 2 is added at 0°C within 15 min to a solution of 11c (926 mg, 1.94 mmol, 2.0 eq), in abs. CH 2 CI 2 (1.5 ml). After stirring for 30 min cyclohexene (0.2 ml) is added and the mixture is warmed to RT (solution B). The clear solution B is added dropwise to suspension A within 1 h. Having stirred for 2 h at RT the mixture is diluted with ethylacetate (200 ml) and filtered through Hyflo Super Cel. The solution is extracted with Na 2 S 2 O 3 solution (100 ml), water (2 x 100 ml) and brine (100 ml). The organic layer is concentrated and the residue dissolved in diethylether (25 ml) and formic acid (5 ml). Having stirred for 3 h the solvents are removed and the residue is puπfied by chromatography on silica gel (ethylacetate/hexane 2:1 ) to give A1c as a colorless oil. 1 H NMR (400 MHz, CDCI 3 ) δ 0.50-1.42 (14 H, m, -Chfe-cCeHn, H^), 1.17 (3 H, t, 7.0 Hz, CO 2 -CH 2 -CH 3 ), 1.34 (3 H, d, 6.5 Hz, H-6 Fuc), 1.94 (1 H, dd, 13.0/5.0 Hz, H- 2βq). 2.24 (1 H, t, 6.5 Hz, C 6 -OH), 3.16 (1 H, dt, 9.5/3.5 Hz, H-5), 3.29 (1 H, t (br), 12.0 Hz, H-1 a χ), 3.52 (1 H, d (br), 2.5 Hz, H-4 Fuc), 3.56 (1 H, dd, 10.0/6.5 Hz, H-6 Gal), 3.57 (1 H, t, 9.5 Hz, H-4), 3.66 (1 H, dd, 10.0/5.5 Hz, H-6' Gal), 3.74 (2 H, m, H-6, H-6'), 3.79 (1 H, dd, 12.0/5.0 Hz, H-1 βq ), 3.84-3.89 (3 H, m, H-3, H-3 Gal, H-5 Gal), 3.92 (1 H, dd, 10.0/2.5 Hz, H- 3 Fuc), 4.05 (1 H, dd, 10.0/3.5 Hz, H-2 Fuc), 4.07-4.15 (3 H, m, -CO 2 -CH 2 -CH 3 , -CH-CH 2 - cC 6 H,ι), 4.38 (1 H, d, 11.5 Hz, -OCH 2 -Ph), 4.43 (1 H, d, 11.5 Hz, -OCH 2 -Ph), 4.47 (1 H, d, 11.5 Hz, -OCH 2 -Ph), 4.48 (1 H, d, 11.5 Hz, -OCH 2 -Ph), 4.57 (1 H, d, 11.5 Hz, -OCH 2 -Ph), 4.61 (1 H, q (br), 6.5 Hz, H-5 Fuc), 4.65 (1 H, d, 8.0 Hz, H-1 Gal), 4.68 (1 H, d, 11.5 Hz, - OCH 2 -Ph), 4.79 (1 H, d, 11.5 Hz, -OCH 2 -Ph), 4.81 (1 H, d, 11.5 Hz, -OCH 2 -Ph), 5.07 (1 H, d, 3.5 Hz, H-1 Fuc), 5.38 (1 H, dd, 10.0/8.0 Hz, H-2 Gal), 5.89 (1 H, d, 3.5 Hz, H-4 Gal), 7.16- 8.12 (30 H, m, Ar-H); MS (FAB/EI) 1229 (M+Na) + . B Preparation of the mimetics Example B(a): Preparation of compounds of the formula IEXM (1 ) Preparation of compound No. B1a [R 4 : CH ∑ CβHn; R T1 : (CH 2 )βC0 2 CH 3 ; R T2 : 3,4-(OCH 3 ) 2 C 6 H 3 ] a) Within 1 h at -35°C in an argon atmosphere trimethylsilyl triflate (15.40 g; 69.50 mmol) is added dropwise to a solution of tetraacetate 1a (12.00 g; 27.81 mmol) and 2a [HO(CH 2 ) θ CO 2 CH 3 ] (7.84 g; 41.70 mmol) in abs. methylene chloride (150 ml). The mixture is warmed to RT within 2 h and triethylamine (15 ml) are added. The mixture is extracted successively with 0.1 n HCI, 0.1 n NaOH, water and saturated NaOH solution (250 ml each). After filtration of the organic phase glycoside 3a is obtained by chromatography on silica gel (ether/hexane 3:1). b) Triacetate 3a (10.40 g, 18.60 mmol) is dissolved in abs. methanol (150 ml), mixed with Amberlite IRA 910 in methanol (15 ml) and stirred at RT for 16 h. The mixture is filtered through Hyflo Super Cef, the solvent is removed and the residue is dried in vacuo to afford giucosamine derivative 4a. c) Giucosamine derivative 4a (3.20 g; 7.39 mmol) is suspended in abs acetonitπle (70 ml). Benzaldehyde dimethylacetate (2.21 ml; 14.71 mmol) is added. Then p-toluenesulfonic acid monohydrate (160 mg) is added and the mixture is stirred at Rt for 16 h and neutralized with NaHC0 3 (400 mg) The solvent is removed in vacuo. Chromatography on silica gel (chloroform/acetone 10:1 ) affords the partially protected carbohydrate 5a d) Giucosamine derivative 5a (452 mg, 0 870 mmol), tetraethylammonium bromide (400 mg; 1 90 mmol) and 1.0 g activated molecular sieves (4 A) are suspended in a mixture of abs methylene chloride (6 0 ml) and abs N,N-dιmethylformamιde (4.3 ml) and stirred in an argon atmosphere at RT for 1 h (suspension A) In a separate reaction vessel a solution of bromine in abs. methylene chloride (0 10 ml in 0 5 ml) is added (argon atmosphere, 0°C) to a solution of fucose derivative 11c (830 mg; 1 74 mmol) in abs. methylene chloride (2.5 ml) within 15 mm. Having stirred for 30 mm cyclohexene (0.25 ml) is added and the mixture is warmed to RT (solution B). The clear solution B is added dropwise to suspension A within 1 h. Having stirred for 16 h the mixture is diluted with ethyl acetate (50 ml) and filtered through Hyflo Super Cel φ The solution is successively extracted with sodium thiosulfate solution (50 ml), twice with water (50 ml each) and saturated NaCl solution (50 ml each). The organic phase is dried over sodium sulfate and concentrated in vacuo Chromatography on silica gel (hexane/ethyl acetate 2.1 ) affords disaccharide 7a e) Disaccharide 7a (1.00 g; 1 .07 mmol), sodium cyano borohydπde (670 mg; 10.70 mmol) and 2.0 g activated molecular sieves (3 A) are suspended in abs. THF (20 ml). At 0°C a saturated solution of HCI gas in abs. ether is added dropwise. Before the complete consumption of 7a ethyl acetate (50 ml) is added and the solution is filtered through Hyflo Super Cel*. The solution is successively extracted twice with NaHCO 3 solution (50 ml each), water (50 ml each) and saturated NaCl solution (50 ml each). The organic phase is dried over Na 2 SO 4 and concentrated in vacuo. Chromatography on silica gel (hexane/ethyl acetate 2:1 ) affords disaccharide 8a. f) Disaccharide 8a (460 mg, 490 mmol) and morpholine (1400 mg, 16.0 mmol) are dissolved in abs. THF (10 ml) (RT; argon atmosphere). Pd[P(Ph) 3 ] 4 (58 mg, 0.050 mmol) is added and the solution is stirred for 15 mm at RT. The volatile components are removed in vacuo. Chromatography on silica gel (ethyl acetate/hexane 1 :1 →2:1) affords amino sugar 9a. g) Ammo sugar 9a (370 mg, 0.433 mmol) and active ester 10a (206 mg, 0.591 mmol) are dissolved in abs. N,N-dιmethylformamide (3.5 ml) (argon atmosphere). 2,6-Lutidine (0.7 ml) is added and the solution is warmed to 70°C for 4 h. Another 50 mg (0.143 mmol) of 10a are added and the solution is stirred for 16 h at 70°C. Then another 30 mg (0.086 mmol) of 10a are added and the solution is warmed to 70°C for 3 h. Ethyl acetate (50 ml) is added and the solution is successively extracted twice with ammonium sulfate solution (50 ml each), NaHCO 3 solution (50 ml each) and saturated NaCl solution (50 ml each) After filtration through cotton wool the solvent is evaporated in vacuo. Chromatography of the residue on silica gel (chloroform/ethyl acetate 3:1) affords amide 11a. h) Disaccharide 11a (190 mg, 0.186 mmol), thiogiycoside 12a (175 mg, 0.279 mmol) and activated molecular sieves (4 A)(500 mg) are suspended in 1.5 ml abs. methylene chloride and stirred in an argon atmosphere for 1 h at RT (solution A). In a separate reaction vessel activated molecular sieves (3 A)(500 mg) are added to a solution of dιmethyl(methylthio)sulfonium triflate 8c (144 mg, 0.558 mmol) in abs. methylene chloride (1.5 ml) and the mixture is stirred for 1 h at RT in an argon atmosphere (solution B). Solution B is added dropwise to solution A within 4 h. Then the mixture is diluted with ethyl acetate (50 ml), filtered through Hyflo Super Cel" and successively extracted with NaHCO 3 solution (50 ml) and twice with saturated NaCl solution (25 ml each). The organic phase is dried over sodium sulfate and concentrated. Chromatography on silica gel (chloroforme/ ethyl acetate 6:1 ) affords trisaccharide 14a. i) Tnsaccharide 14a (205 mg, 0.129 mmol) is dissolved in abs. methanol (5 ml) in an argon atmosphere Then 0.065 ml of a 2.0 M solution of sodium methanolate (0.13 mmol) in abs. methanol are added and the solution is stirred for 3 h at RT. The solution is neutralized by the addition of acetic acid (0.01 ml) and the solvent is removed in vacuo.Chromatography on silica gel (chloroform/acetone 2:1 ) affords partially deprotected tnsaccharide 15a. j) Tnsaccharide 15a (80 mg, 0.063 mmol) is dissolved in an argon atmosphere in abs. benzene (2 ml), dibutyltinoxide (28 mg, 0.110 mmol) is added and the mixture is heated under reflux for 16 h The solvent is removed, the residue is dried for 1h at 40°C in high vacuum and dissolved in abs dimethoxyethane (1.6 ml) A solution of triflate 16a (125 mg, 0 315 mmol) in abs dimethoxyethane (1 ml) is added and the mixture is stirred for 6 h at 40°C. Then 25 ml fluoride solution is added and the solution is extracted twice with chloroform (25 ml each). The solution is dried with sodium sulfate and the solvent is removed Chromatography on silica gel (chloroform/acetone 15:1) affords tnsaccharide 17a. k) Tnsaccharide 17a (44 mg, 29 μmol) is dissolved in a mixture of dioxane (4 ml), water (1.5 ml) and acetic acid (0.25 ml). Having thoroughly degassed palladiumhydroxide (20%) on coal (100 mg) is added. The suspension is stirred for 15 min in an argon atmosphere. Then the mixture is hydrogenated for 16 h at RT. The catalyst is filtered off through a HPLC filter, the solvent is removed, the residue is dissolved in water/methanol (2:1) and passed through a sodium ion exchange column (water). Product containing fractions are combined and concentrated. The residue is dissolved in water and lyophilized to obtain compound B1a Η-NMR (400 MHz, D 2 O) δ 0.50-1.70 (25 H, m, -O-CH 2 (CH 2 ) 6 CH 2 CO 2 CH 3 , -CH^c- C 6 H„), 1.07 (3 H, d, 6.5 Hz, 3 x H-6 Fuc), 2.06 (2 H, t, 7.5 Hz, 3.30 (1 H, dd, 9 5/3 0 Hz), 3.42-4.15 (17 H, m), 3.54 (3 H, s, -CO 2 CH 3 ), 3.77 (3 H, s, Ar-OCH 3 ), 3.78 (3 H, s, Ar-OCH 3 ), 4.37 (1 H, d, 8.0 Hz, H-1 Gal), 4.55 (1 H, s (br), H-1 Glc), 4.71 (1 H, q, 6.5 Hz, H-5 Fuc), 5.02 (1 H, d, 3.5 Hz, H-1 Fuc), 7.01 (1 H, d, 8.5 Hz, Arhf), 7.32 (1 H, d, 2.0 Hz, ArH), 7.38 (1 H, dd, 8.5/2.0 Hz, ArH); MS (FAB/EI) 974 (M - Na). (2) Preparation of compound No. B2a [R 4 : CH 2 C 6 Hn; R T1 : (CH 2 ) 8 Cθ 2 CH 3 ; R T2 : 3,4-(OH) 2 C 6 H 3 ] Starting with ammo sugar 9a (150 mg, 0.175 mmol) and active ester 28a (175 mg, 0.351 mmol) compound No. B2a is prepared according to Example B(a)(1). 1 H-NMR (400 MHz, D 2 O) δ 0.60-1 73 (25 H, m, -O-CH 2 (CH 2 ) 6 CH 2 CO 2 CH 3 , -CH 2 -c-C B H u ), 1.07 (3 H, d, 6.5 Hz, 3 x H-6 Fuc), 2 13 (2 H, t, 7.5 Hz, -CH 2 CH 2 CO 2 Me), 3.32 (1 H, dd, 9.5/3.0 Hz), 3.44-3.95 (17 H, m), 3.57 (3 H, s, -CO 2 CH 3 ), 4.39 (1 H, d, 8.0 Hz, H-1 Gal), 4.56 (1 H, s (br), H-1 Glc), 4.71 (1 H, q, 6.5 Hz, H-5 Fuc), 5.02 (1 H, d, 3.5 Hz, H-1 Fuc), 6.87 (1 H, d, 8.5 Hz, ArH), 7.21 (1 H, dd, 8.5/2.0 Hz, ArH), 7.24 (1 H, d, 2.0 Hz, ArH); MS (FAB/EI) 946 (M - H) " . (3) Preparation of compound No. B3a [R 4 : C 6 Hn; R T1 : (CH 2 ) 8 CO 2 CH 3 ; R T2 : 3,4-(OCH 3 ) 2 C 6 H 3 ] a) Starting from trisaccharide 15a (77 mg, 0.061 mmol) and triflate 23a (120 mg, 0.303 mmol) compound No. B3a is prepared according to Example B(a)(1 ). H-NMR (400 MHz, D 2 O) δ 0.50-1 .63 (23 H, m, -O-CH 2 (CH 2 ) 6 CH 2 CO 2 CH 3 , c-C 6 H ), 1.06 (3 H, d, 6.5 Hz, 3 x H-6 Fuc), 2.04 (2 H, t, 7.5 Hz, -CH 2 CH 2 CO 2 Me), 3.26 (1 H, dd, 9.5/3.0 Hz), 3.39-3.92 (17 H, m), 3.54 (3 H, s, -CO 2 CH 3 ), 3.77 (3 H, s, Ar-OCH 3 ), 3.78 (3 H, s, Ar-OCH 3 ), 4.36 (1 H, d, 8.0 Hz, H-1 Gal), 4.55 (1 H, s (br), HA Glc), 4.71 (1 H, q, 6.5 Hz, H-5 Fuc), 5.00 (1 H, d, 3.5 Hz, H-1 Fuc), 6.98 (1 H, d, 8.5 Hz, ArH), 7.31 (1 H, d, 2.0 Hz, ArH), 7.37 (1 H, dd, 8.5/2.0 Hz, ArH); MS (FAB/EI) 960 (M - Na) ' . (4) Preparation of compound No. B4a [R 4 : CH 2 C 6 Hn; R T1 : (CH 2 ) B Cθ 2 a; R T2 : 3,4-(OCH 3 ) 2 C 6 H 3 ] Methyl ester B1a (10 mg, 0.010 mmol) is dissolved in water (1 ml), mixed with 2 N NaOH (20 μl) and stirred for 16 h at RT. Reverse phase chromatography on RP 18 (water→ water/methanol 3:1 ) affords carboxylate B4a. 'H-NMR (400 MHz, D 2 O) δ 0.49-1.70 (25 H, m, -O-CH 2 (CH 2 ) 6 CH 2 CO 2 CH 3 , -CH^-c-CeHu), 1.06 (3 H, d, 6.5 Hz, 3 x H-6 Fuc), 1.92 (2 H, t (br), 7.5 Hz, -CH 2 Ctf 2 CO 2 Me), 3.28 (1 H, dd, 9.5/3.0 Hz), 3.42-4.15 (17 H, m), 3.77 (3 H, s, Ar-OCH 3 ), 3.78 (3 H, s, Ar-OCH 3 ), 4.36 (1 H, d, 8.0 Hz, H-1 Gal), 4.53 (1 H, s (br), H-1 Glc), 4.71 (1 H, q, 6.5 Hz, H-5 Fuc), 5.02 (1 H, d, 3.5 Hz, H-1 Fuc), 7.00 (1 H, d, 8.5 Hz, ArH), 7.31 (1 H, d, 2.0 Hz, ArH), 7.37 (1 H, dd, 8.5/2.0 Hz, ArH); MS (FAB/EI) 1004 (M - H)-. Example B(b): Preparation of compounds of the formula l E χ(b) (1 ) Preparation of compound No. B1 b [R B6 : H, R B7 : C(O)CH(C 6 H 5 ) 2 ] A solution of commercially available diphenylacetyl chloride (11.3 mg, 0.049 mmol, 1.5 eq.) in THF (0.5 ml) is added at 0°C to a solution of A1b (20 mg, 0.033 mmol) in THF/H 2 O 1/1 (2 ml). The pH of the reaction mixture is adjusted to 8-10 by the addition of 1 N NaOH solution and maintained at 8-10 throughout the whole reaction. After 18 h additional diphenylacetyl chloride (3.7 mg, 0.016 mmol, 0.5 eq.) is added and after a total of 42 h the reaction mixture is partially evaporated to remove THF. The now aqueous solution is purified by RP C18 (column size 1 x 10 cm) through stepwise elution with acetonitrile/water 30/70 and then acetonitrile/water 40/60. The product obtained is further purified by flash chromatography on silica (ethyl acetate/isopropanol/water = 4/2/1 ) to give after freeze drying B1b as a white foam. C 4 ,H 56 NO, 5 Na (MW=825.88): MS (FAB positive mode, THG) 826 (M+H), 804 (M- Na+H). 'H NMR (500 MHz, D 2 O) δ 7.42-7.22 (m, 20H), 5.16 (s, 1 H, CHPh 2 ), 4.78 (d, 1 H, Fuel ), 4.64 (q, 1 H, Fuc5), 4.46 (d, 1 H, Gall), 4.02-3.88 (m, 3H), 3.87 (d, 1 H, Gal4), 3.82 (dd, 1 H, Fuc3), 3.78-3.65 (m, 5H), 3.62-3.49 (m, 3H), 3.45-3.32 (m, 4H), 2.19-2.11 (m, 1H), 1 .79-1.72 (m, 1 H), 1.68-1.46 (m, 8H), 1.22-1.08 (m, 6H, including at 1.15 (d, Fuc6)), 0.96- 0.82 (m, 2H). The following compounds are prepared in analogy to the above example whereas for the purification one to three of the following purification steps are applied in any order desired to obtain analytically pure compounds: a) Reverse phase C18 column chromatography (column size 1 x 10 cm) using stepwise elution with acetonitrile/water starting with low acetonitrile content ending with high acetonitrile content. b) Flash chromatography on silica (ethyl acetate/isopropanol/water = 4/2/1 ) c) P2 gelfiltration using water as eluent. (2) Preparation of compound No. B2b [R B6 : H, R B7 : CtOJCβH,,] (MW=741.80): MS (FAB positive mode, THG) 742 (M+H), 720 (M-Na+H). *H NMR (500 MHz, D 2 O) δ 4.86 (d, 1H, Fuel), 4.67 (q, 1 H, Fuc5), 4.48 (d, 1 H, GaM ), 4.05-3.91 (m, 3H), 3.87 (d, 1 H, Gal4), 3.83 (dd, 1 H, Fuc3), 3.77 (d, 1H, Fuc4), 3.74 (dd, 1H, Fuc2), 3.72-3.68 (m, 2H), 3.63-3.55 (m, 3H), 3.53-3.40 (m, 4H), 3.36 (dd, 1H, Gal3), 2.27-2.16 (m, 2H), 1.79-1.68 (m, 5H), 1.68-1.47 (m, 9H), 1.37-1.08 (m, 11 H, including at 1.17 (d, Fuc6)), 0.97-0.83 (m, 2H). (3) Preparation of compound No. B3b [R B6 : H, R B7 : C(0)C 6 H s ] (MW=735.76): MS (FAB negative mode, THG) 712 (M-Na). 1 H NMR (400 MHz, D 2 O) δ 7.66 (d, 2H), 7.52 (m, 1 H), 7.42 (t, 2H), 4.93 (d, 1 H, Fuel), 4.64 (q, 1 H, Fuc5), 4.42 (d, 1 H, GaM ), 4.04-3.90 (m, 3H), 3.88-3.75 (m, 3H including: 3.85 (d, 1 H, Gal4), 3.80 (dd, 1 H, Fuc3)), 3.75-3.68 (m, 2H, Fuc4, Fuc2), 3.69-3.36 (m, 8H), 3.32 (dd, 1 H, Gal3), 2.18-2.10 (m, 1 H), 1.73-1.65 (m, 1 H), 1.65-1.39 (m, 8H), 1.21-1.00 (m, 6H, including at 1.13 (d, Fuc6)), 0.92-0.73 (m, 2H). (4) Preparation of compound No. B4b [R B6 : H, R B7 : C(0)C 6 H 4 (4-OCH 3 )] C 35 H 52 NO, 6 Na (MW=765.78): MS (FAB negative mode, THG) 742 (M-Na). 'H NMR (400 MHz, D 2 O) δ 7.66 (m, 2H), 6.98 (m, 2H), 4.92 (d, 1 H, Fuel ), 4.63 (q, 1 H, Fuc5), 4.42 (d, 1 H, Gall ), 4.04-3.85 (m, 3H), 3.83-3.75 (m, 6H including: 3.81 (d, 1 H, GaM), 3.79 (s, 3H, OCH 3 ), 3.78 (dd, 1 H, Fuc3)), 3.73-3.68 (m, 2H, Fuc4, Fuc2), 3.68-3.35 (m, 8H), 3.30 (dd, 1 H, Gal3), 2.18-2.11 (m, 1 H), 1.73-1.65 (m, 1 H), 1.65-1.39 (m, 8H), 1.21-1.00 (m, 6H, including: 1.10 (d, Fuc6)), 0.92-0.75 (m, 2H). (5) Preparation of compound No. B5b [R B6 : H, R Br : C(0)C 6 H 3 (3,4-OCH 3 ) 2 ] CaeH^NO^Na (MW=795.81): MS (FAB negative mode, THG) 794 (M-H), 772 (M-Na). 1 H NMR (500 MHz, D 2 O) δ 7.40 (dd, 1 H), 7.35 (d, 1 H), 7.06 (d, 1 H), 4.98 (d, 1 H, Fuel), 4.69 (q, 1 H, Fuc5), 4.49 (d, 1H, Gall ), 4.05 (m, 1 H), 3.99 (m, 1 H), 3.93 (m, 1 H), 3.90-3.81 (m, 9H including: 3.87 (s, 3H, OCH 3 ), 3.86 (s, 3H, OCH 3 ), 3.75 (dd, 1 H, Fuc3)), 3.80-3.75 ( , 2H, Fuc4, Fuc2), 3.74-3.54 (m, 6H), 3.54-3.44 (m, 2H), 3.36 (dd, 1 H, Gal3), 2.24-2.19 (m, 1H), 1.78-1.72 (m, 1 H), 1.69-1.45 (m, 8H), 1.24-1.08 (m, 6H, including: 1.17 (d, Fuc6)), 0.96-0.82 (m, 2H). (6) Preparation of compound No. B6b [R B6 : H, R B7 : C(0)C 6 H 4 (4-CI)] C 34 H 49 NOι 5 NaCI (MW=770.20): MS (FAB negative mode, THG) 768 (M-H), 746 (M-Na). 'H NMR (400 MHz, D 2 O) δ 7.62 (m, 2H), 7.42 (m, 2H), 4.92 (d, 1 H, Fuel ), 4.63 (q, 1 H, Fuc5), 4.42 (d, 1H, Ga!1), 4.04-3.84 (m, 3H), 3.83-3.75 (m, 3H including: 3.81 (d, 1H, Gal4), 3.78 (dd, 1 H, Fuc3)), 3.73-3.68 (m, 2H, Fuc4, Fuc2), 3.68-3.35 (m, 8H), 3.30 (dd, 1 H, Gal3), 2.18-2.10 (m, 1 H), 1.73-1.65 (m, 1H), 1.65-1.37 (m, 8H), 1.21-1.00 (m, 6H, including: 1.10 (d, Fuc6)), 0.92-0.72 (m, 2H). (7) Preparation of compound No. B7b [R B6 : H, R B7 : C(0)C 6 H 4 (4-N0 2 )] C 34 H 49 N 2 O, 7 Na (MW=780.75): MS (FAB negative mode, THG) 779 (M-H), 757 (M-Na). 1 H NMR (400 MHz, D 2 O) δ 8.25 (m, 2H), 7.83 (m, 2H), 4.92 (d, 1H, Fuel), 4.63 (q, 1 H, Fuc5), 4 42 (d, 1 H, GaM ), 4.04-3.84 (m, 4H), 3.83-3.76 (m, 2H, Gal4, Fuc3), 3.74-3.58 (m, 5H), 3.68-3.35 (m, 5H), 3.29 (dd, 1 H, Gal3), 2.18-2.08 (m, 1H), 1.72-1.64 (m, 1 H), 1.64-1.36 (m, 8H), 1.21 -0.96 ( , 6H, including: 1.10 (d, Fuc6)), 0.90-0.75 (m, 2H). (8) Preparation of compound No. B8b [R B6 : H, R B7 : C(0)C 6 H 4 (4-C 6 H 5 )] C 40 H 55 NO,5Na (MW=812.86): MS (FAB positive mode, THG) 790 (M-Na+H). 1 H NMR (400 MHz, D 2 O) δ 7.78 (d, 2H), 7.75-7.65 (m, 4H), 7.48 (t, 2H), 7.42 (m, 1H), 4.97 (d, 1H, Fuel), 4.66 (q, 1 H, Fuc5), 4.45 (d, 1 H, Gall), 4.08-3.80 (m, 6H), 3.80-3.72 (m, 2H, Fuc4, Fuc2), 3.72-3.62 (m, 3H), 3.62-3.38 (m, 5H), 3.32 (dd, 1 H, Gal3), 2.21-2.13 (m, 1 H), 1.76-1.68 (m, 1 H), 1.68-1.40 (m, 8H), 1.22-1.00 (m, 6H, including: 1.13 (d, Fuc6)), 0.95-0.78 (m, 2H). (9) Preparation of compound No. B9b [R B6 : H, R B7 : C(0)-2-naphthyl] C 38 H 52 NO, 5 Na (MW=785.82): MS (FAB negative mode, THG) 762 (M-Na). *H NMR (500 MHz, D 2 O) δ 8.28 (s, 1 H), 8.02-7.93 (m, 3H), 7.78-7.74 (m, 1 H), 7.65-7.58 (m, 2H), 5.01 (d, 1 H, Fuel ), 4.70 (q, 1 H, Fuc5), 4.49 (d, 1 H, Gall ), 4.01-3.97 (m, 2H), 3.96-3.85 (m, 4H including Gal4, Fuc3), 3.81-3.76 (m, 2H, Fuc4, Fuc2), 3.76-3.68 (m, 3H), 3.65-3.45 (m, 5H), 3.36 (dd, 1 H, Gal3), 2.24-2.18 (m, 1H), 1.79-1.72 (m, 1 H), 1.72-1.46 (m, 8H), 1.24-1.06 (m, 6H, including: 1.10 (d, Fuc6)), 1.00-0.81 (m, 2H). (10) Preparation of compound No. B10b [R B6 : H, R B7 : C(0)OCH2C β H s ] C 35 H 52 NO, 6 Na (MW=765.82): MS (FAB negative mode, THG) 742 (M-Na). 'H NMR (500 MHz, D 2 O) δ 7.42-7.33 (m, 5H), 5.06 (d, 2H, ChbPh), 4.86 (d, 1H, Fuel ), 4.66 (q, 1H, Fuc5), 4.45 (d, 1H, GaM ), 4.01 -3.95 (m, 1 H), 3.95-3.89 (m, 2H), 3.85 (d, 1 H, Gal4), 3.81 (dd, 1 H, Fuc3), 3.76-3.66 (m, 4H), 3.62-3.54 (m, 3H), 3.44-3.31 (m, 5H), 2.18-2.12 (m, 1 H), 1.76- 1.71 (m, 1H), 1.65-1.44 (m, 8H), 1.21-1.03 (m, 6H, including: 1.13 (d, Fuc6)), 0.94-0.80 (m, 2H). (11 ) Preparation of compound No. B11 b [R B6 : H, R B7 : C(O)NHC 6 H s ] A solution of phenylisocyanate (4 mg, 0.033 mmol, 1.2 eq.) in 0.5 N NaOH is added at 0 C C to a solution of A1b (17 mg, 0.027 mmol) in 0.5 N NaOH (1 ml). Addition of phenylisocyanate is continued until after 11 d a total amount of 6 equivalents is added. The product is puπfied by flash chromatography on silica (ethyl acetate/isopropanol/water = 4/2/1 ), filtered on Dowex ion exchange resin Na + form eluting with water, further purified by P2 gelfiltration using water as eluent and again filtered on Dowex Na + form to give after freeze drying B11b as a white foam. (MW=750.77): Η NMR (400 MHz, D 2 O) δ 7.27 (m, 2H), 7.18 (d, 2H), 7.03 (t, 1 H), 4.86 (d, 1 H, Fuel), 4.64 (q, 1H, Fuc5), 4.39 (d, 1 H, Gall), 4.08- 3.85 (m, 3H), 3.84 (s, 1H, Gal4), 3.76 (dd, 1 H, Fuc3), 3.72-3.64 (m, 2H, Fuc4, Fuc2), 3.63- 3 46 (m, 6H), 3.46-3.28 (m, 4H), 2.16-2.06 (m, 1 H), 1.73-1.63 (m, 1H), 1.72-1.38 (m, 8H), 1.20-0.97 (m, 6H, including: 1.09 (d, Fuc6)), 0.92-0.72 (m, 2H). (12) Preparation of compound No. B12b [R B6 : H, R B7 : SO 3 Na] Commercially available sulfur tnoxide pyπdine complex (7.8 mg, 0.049 mmol, 1.5 eq.) is added to a solution of A1b (20 mg, 0.033 mmol) in H 2 O (2 ml) with enough 2 N NaOH to obtain a pH of above 1 1. After 16 h another portion of sulfur trioxide pyridine complex (7.8 mg, 0.049 mmol, 1.5 eq.) is added. After 40 h the reaction mixture is evaporated and purified by P2 gelfiltration eluting with water and the product is subsequently purified by C18 reverse phase chromatography (using a SepPac syringe adapter) through stepwise elution with acetonitrile/water 10/90 → 90/10 to give after evaporation and freeze drying B12b as a white foam. C 27 H 45 NOι 7 SNa 2 (MW=733.70): MS (FAB negative mode, THG) 710 (M-Na), 688 (M-2Na+H). 1 H NMR (400 MHz, D 2 O) δ 4.98 (d, 1 H, Fuel), 4.68 (q, 1 H, Fuc5), 4.42 (d, 1 H, Gall), 3.99-3.86 (m, 3H), 3.82 (d, 1H, Gal4), 3.78 (dd, 1 H, Fuc3), 3.73-3.67 (m, 2H, Fuc4, Fuc2), 3.67-3.59 (m, 2H), 3.58-3.48 (m, 2H), 3.48-3.32 (m, 4H), 3.30 (dd, 1H, Gal3), 3.12 (dd, 1 H), 2.17-2.08 (m, 1 H), 1.74-1.66 (m, 1 H), 1.63-1.39 (m, 8H), 1.21-1.00 (m, 6H, including at 1.12 (d, Fuc6)), 0.92-0.75 (m, 2H). (13) Preparation of compound No. B13b [R B6 : H, R B7 : CH 2 C 6 H 5 ] and compound No. B14b [R ,B β 6 6 :. »B7. CH 2 C β H 5 , R°': CH Ϊ C 6 H S ] Borane pyndine complex (BH 3 .C 5 H 5 N, 0.013 ml, 0.131 mmol) is added to a mixture of A1b (40 mg, 0.066 mmol), benzaldehyde (0.033 ml, 0.328 mmol) and freshly dried 4A molecular sieves (ca. 500 mg) in dry MeOH (0.5 ml). After 20 h two new products have formed and the reaction mixture is filtered, evaporated and the two products are separated by flash chromatography on silica (ethyl acetate/isopropanol/water = 4/2/1 ) to give in the order of elution fraction 1 and fraction 2 Fraction 1 is further purified by P2 gelfiltration eluting with water and then filtered on Dowex ion exchange resin Na + form eluting with water to give after freeze drying B14b as a white foam. Fraction 2 is also further purified by P2 gelfiltration eluting with water and then filtered on Dowex ion exchange resin Na + form eluting with water to give after freeze drying B13b as a white foam B14b C 4 ,H 58 NOι 4 Na (MW=811.91): MS (FAB negative mode, THG) 788 (M-Na) 1 H NMR (400 MHz, D 2 O) δ 7 41 (m, 10H), 4.64 (d, 1 H, Fuel ), 4 43 (q, 1 H, Fuc5), 4.37 (d, 1 H, GaM ), 4 46-4 12 (m, 3H), 3.93-3.83 (m, 2H), 3.81 (s, 1 H Gal4), 3.78-3.58 (m, 7H), 3.58-3.37 (m, 3H), 3 37-3.19 (m, 3H), 2.12-2.02 (m, 1 H), 1 74-1.65 (m, 1 H), 1.73-1.38 (m, 8H), 1.22-0.97 (m, 6H, including 1 08 (d, Fuc6)), 0.92-0.75 (m, 2H). B13b C 34 H 52 NO, 4 Na (MW=721.77) MS (FAB negative mode, THG) 698 (M-Na) 1 H NMR (400 MHz, D 2 O) δ 7.38 (m, 5H), 4 72 (d, 1H, Fuel ), 4.52 (q, 1 H, Fuc5), 4 41 (d, 1H, GaM ), 4 19 (d, 1 H, CH 2 Ph), 4 14 (d, 1 H, CH 2 Ph), 4.00-3 84 (m, 3H), 3.81 (s, 1 H, Gal4), 3.73 (dd, 1 H, Fuc3), 3.69 (d, 1 H), 3.68-3 59 (m, 3H), 3.59-3 45 (m, 4H), 3 44-3.32 (m, 2H), 3.29 (dd, 1 H, Gal3), 3 18 (dd, 1 H), 2.18-2 08 (m, 1 H), 1.73-1.65 (m, 1 H), 1.72-1.38 (m, 8H), 1.21-0.95 (m, 6H, including: 1.09 (d, Fucδ)), 0.92-0.72 (m, 2H). The following compounds are prepared in analogy to the above examples: Example B(c): Preparation of compounds of the formula IE X(C) (1 ) Preparation of compound No. B1 c [R 5 : CH 2 OH] To a solution of A1c (75 mg, 0.062 mmol) in dioxane (1 ml) 0.5 ml of 0.5 N NaOH are added and the mixture is stirred at RT for 1 h. Then, 0.05 ml of acetic acid are added and the solvent is removed in vacuo. The residue is dissolved in abs. methanol (1 ml) and hydrogenated in the presence of Pd(10%) on charcoal (75 mg) for 16 h at RT. The catalyst is filtered off, the solvent is removed and the residue is purified by reversed phase chromatography (RP18, water/methanol 3:1→1 :2). Passage through a sodium ion exchange column followed by lyophilization gives B1c as a colorless powder. 1 H NMR (400 MHz, D 2 O) δ 0.75-1.72 (13 H, m. -Ctb-cCβHu, H-2.J, 1.09 (3 H, d, 6.5 Hz, H-6 Fuc), 2.12 (1 H, dd, 13.0/5.0 Hz, H- 2 βq ), 3.28 (2 H, m, H-5, H-3 Gal), 3.38 (1 H, t (br), 12.5 Hz, H-1^), 3.47 (1 H, t, 9.5 Hz, H-4), 3.50 (1 H, m, H-5 Gal), 3.52 (1 H, t, 8.5 Hz, H-2 Gal), 3.62 (2 H, m, H-6 Gal, H-6' Gal), 3.67 (1 H, dd, 10.5/4.0 Hz, H-2 Fuc), 3.69 (1 H, d (br), 3.0 Hz, H-4 Fuc), 3.74 (1 H, dd, 7.0/4.0 Hz, H-6), 3.78 (1 H, dd, 10.0/3.0 Hz, H-3 Fuc), 3.80 (1 H, d (br), 3.0 Hz, H-4 Gal), 3.84 (1 H, dd, 7.0/2.0 Hz, H-6'), 3.88 (2 H, m, H-1,*,, -CH-CH 2 -cC 6 Hn), 3.94 (1 H, td, 9.5/5.0 Hz, H-3), 4.41 (1 H, d, 8,5 Hz, H-1 Gal), 4.71 (1 H, q (br), 6.5 Hz, H-5 Fuc), 4.86 (1 H, d, 3.5 Hz, H-1 Fuc); MS (FAB/EI) 632 (M+H) + . (2) Preparation of compound No. B2c [R 5 : CH 3 ] a) A solution of A1c (120 mg, 0.10 mmol), 13c (53 mg, 0.20 mmol, 2 eq) N-hydroxysuccinimide (2.3 mg, 0.02 mmol, 0.2 eq) and abs. pyridine (31.6 mg, 0.40 mmol, 4 eq) in abs. benzene (1 ml) is heated under reflux for 2 h. The clear solution is diluted with ethylacetate (20 ml) and extracted with HCI (0.5 n, 2 x 20 ml), NaHCO 3 (20 ml) and brine (20 ml). The solvent is removed and the residue subjected to chromatography (silicagel, toluene/ethylacetate 5:1 ). Compound 14c is isolated as a colorless foam. b) A solution of 14c (105 mg, 0.073 mmol), Bu 3 SnH (32 mg, 0.110 mmol, 1.5 eq), N,N'-azo- bisisobutyronitriie (2 mg) in 3 ml of abs. benzene is heated under reflux for 1 h. Then, additional Bu 3 SnH (32 mg) and N,N'-azobisisobutyronitrile (2 mg) are added and heating is continued for 1 h. The solvent is removed and the residue subjected to chromatography (toluene/ethylacetate 4:1). Compound 15c is isolated as a colorless oil. c) A solution of 15c (15.0 mg, 0.013 mmol) in dioxane (1 ml), methanol (0.3 ml) and 2 N NaOH (0.2 ml) is stirred at RT for 24 h. Then, 0.1 ml acetic acid is added, the solvents are removed and the residue is passed through a short column (silicagel, isopropanol/ethylace- tate/water 10:10:1 ). Following evaporation of the solvents the crude material is dissolved in a mixture of methanol (1.5 ml) and acetic acid (0.1 ml). Palladium hydroxide (20%) on carbon (20 mg) is added and the mixture is hydrogenated at ambient pressure at RT for 16 h. The solvents are removed and the residue is purified by reversed phase chromatography (RP18, water/methanol 5:1 →2:1 ). Product containing fractions are combined, the solvent is removed, the residue is dissolved in water and passed through a sodium ion exchange column. Following lyophilization compound B2c is isolated as a colorless powder. *H NMR (400 MHz, CDCI 3 ) δ 0.77-1.72 (14 H, m, -CHrcCeH,,, H-2ax), 1.10 (3 H, d, 6.5 Hz, H-6 Fuc), 1.22 (3 H, d, 6.5 Hz, H-6), 2.13 (1 H, dd (br), 13.0/5.0 Hz, H-2βq), 3.19 (1 H, t, 9.0 Hz, H-4), 3.30 (1 H, dd, 9.5/3.0 Hz, H-3 Gal), 3.36 (1 H, dq, 9.0/6.5 Hz, H-5), 3.41 (1 H, t (br), 12.0 Hz, H-1 a ), 3.51 (1 H, t, 6.0 Hz, H-5 Gal), 3.53 (1 H, dd, 9.5/8.0 Hz, H-2 Gal), 3.63 (2 H, d, 6.0 Hz, H-6 Gal, H-6' Gal), 3.68 (1 H, dd, 10.5/4.0 Hz, H-2 Fuc), 3.72 (1 H, d (br), 3.5 Hz, H- 4 Fuc), 3.78 (1 H, dd, 10.5/3.5 Hz, H-3 Fuc), 3.82 (1 H, d (br), 3.0 Hz, H-4 Gal), 3.83 - 3.97 (3 H, m, -CH-CH 2 -cC 6 Hιι, H-1 eq , H-3), 4.41 (1 H, d, 8.0 Hz, H-1 Gal), 4.69 (1 H, q, 6.5 Hz, H- 5 Fuc), 4.95 (1 H, d, 4.0 Hz, H-1 Fuc); MS (FAB/EI) 617 (M+H) + . (3) Preparation of compound No. B3c [R 5 : C0 2 Na] a) To a solution of A1c (150 mg, 0.124 mmol) in abs. CH 2 CI 2 (5 ml) 16c (158 mg, 0.373 mmol) is added and stirred at RT for 1 h. Then, an aqueous solution (20 ml) of Na 2 S 2 O 3 (400 mg) and NaHCO 3 (200 mg) is added. The mixture is extracted with CH 2 CI 2 (2 15 ml), the combined organic layers are dried over Na 2 SO 4 and the solvent is removed. The residue is dissolved in a mixture of 2-methyl-2-butene (3 ml) and tert. butanol (4 ml). An aqueous solution (3 ml) of NaCIO 2 (250 mg) and NaH 2 PO 4 (200 mg) is added and the heterogeneous mixture is stirred vigorously for 1 h. Then, water (20 ml) and CH 2 CI 2 (20 ml) are added, the layers are separated and the aqueous layer is extracted with CH 2 CI 2 (2 x 20 ml). The combined organic layers are dried with Na 2 SO 4 , the solvent is removed and the residue is subjected to flash chromatography (silicagel, isopropanol/ethylacetate/water 25:25:5). Compound 17c is isolated as a colorless foam. b) A solution of 17c (30.0 mg, 0.025 mmol) in dioxane (1.5 ml), methanol (0.5 ml) and 2 N NaOH (0.3 ml) is stirred at RT for 24 h. Then, 0.1 ml acetic acid is added, the solvents are removed and the residue is passed through a short column (silicagel, isopropanol/ethylacetate/water 10:10:1). Following evaporation of the solvents the crude material is dissolved in a mixture of methanol (1.5 ml) and acetic acid (0.3 ml). Palladium hydroxide (20 %) on carbon (60 mg) is added and the mixture is hydrogenated at ambient pressure at RT for 16 h. The solvents are removed and the residue is purified by reversed phase chromatography (RP18, water/methanol 5:1→2:1). Product containing fractions are combined, the solvent is removed, the residue is dissolved in water and passed through a sodium ion exchange column. Following lyophilization compound B3c is isolated as a colorless powder. 1 H NMR (400 MHz, CDCI 3 ) δ 0.75-1.72 (14 H, m, -CH cCeJHn, H-1ax), 1.09 (3 H, d, 6.5 Hz, H-6 Fuc), 2.07 (1 H, m, H-2 βq ), 3.27 (1 H, dd, 9.5/3.0 Hz, H-3 Gal), 3.42 (1 H, ddd, 12.0/10.0/3.0 Hz, 3.50 (1 H, dd, 9.5/8.0 Hz, H-2 Gal), 3.52 (1 H, dt, 0.5 7.5 Hz, H-5 Gal), 3.59-3.71 (6 H, m, H-4, H-5, H-2 Fuc, H-4 Fuc, H-6 Gal, H-6' Gal), 3.77 (1 H, dd, 10.5/3.5 Hz, H-3 Fuc), 3.82 (1 H, dd, 3.0/0.5 Hz, H-4 Gal), 3.87 (1 H, dd, 10.0/3.5 Hz, -CH-CH 2 - cC 6 H„), 3.93-4.02 (2 H, m, H-1 βq , H-3), 4.37 (1 H, d, 8.0 Hz, H-1 Gal), 4.47 (1 H, q, 6.5 Hz, H-5 Fuc), 4.89 (1 H, d, 4.0 Hz, H-1 Fuc); MS (FAB/EI) 617 (M+H)\ C. Biological Activities of the Mimetics Example C1 : Ligand Binding Assay for Determination of IC S0 Values-conserved use of positive controls This assay is performed as disclosed in Example D1 of WO 97/19,105 the contents thereof relating to this assay being incorporated hereinwith and wherein the E-selectin/human IgG chimera are cloned and expressed according to Kolbinger, F., Patton, J.T., Geisenhoff, G., Aenis, A., Li, X., Katopodis, A., Biochemistry 35:6385-6392 (1996). In this assay the compounds of formula I have an RIC 50 value of from 0.01 to 1.0. * RIC 50 means IC 50 (test compound)/IC 5 o(control compound A) Example C2: Cell Adhesion under Flow Conditions This assay is performed as disclosed in Example D3 of WO 97/19,105 the contents thereof relating to this assay being incorporated hereinwith. The compounds of formula I show a reduction of number of interacting cells at 50 μM of in the range from 40 % to 90 %.

Claims: WHAT IS CLAIMED IS: 1. A compound of the formula I (I) wherein R 1 is an S-configurated methyl substituted with a carboxy and one other substituent; R 2 is hydrogen, C Cι 2 alkyl or C 6 aryl; where the alkyl and the aryl are unsubstituted or substituted by one or more substituents; and Z is a group of the formula lla, Mb or lie wherein X is -C(O)-, -C(S)-, -S(O) 2 -, -C(O)Q- or -C(S)Q-, in which Q is NH, O, S, S-C,-C 6 alkylene, NH-C,-C 6 alkylene or O-C C 6 alkylene; R T1 is CrC 12 alkyl, C 2 -Cι 2 alkenyl, Cι-Cι 2 alkoxy, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -C ii heterocycloalkyl, C 2 -Cnheterocycloalkenyl, C6-C, 0 aryl, C 6 -Cιoaryloxy, Cs-Cgheteroaryl, Cs-Cgheteroaryloxy, C 7 -C,ιaralkyl, C 7 -Cn aralkyloxy, C 6 -Cι 0 heteroaralkyl, C e -Cnaralkenyl or C 7 -Cι 0 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents; and R T2 is C 3 -Cι 2 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -Cn heterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -C 10 aryl, C 6 -Cι 0 aryloxy, C 5 -C 9 heteroaryl, Cs-Cgheteroaryloxy, C 7 -Cι,aralkyl, C 7 -Cnaralkyl- oxy, Ce-Cioheteroaralkyl, C 8 -Cnaralkenyl or C -Cι 0 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents; R B5 is NH 2 , primary amino, secondary amino or amido; R 5 is X'-R T1C , C(O)NR T2C R T3C , C(O)R T4C or C(O)OR T5C , wherein X' is C,-C 4 alkylene, R T1C is hydrogen, halogen, Cι-C 12 alkyl, Ci-Cnheteroalkyl, C 3 -C 12 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -Cι heterocycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -, Cι 0 - or C 4 aryl, C 2 -C 9 heteroaryl, C 7 -C, aralkyi, C 6 -Cι 0 heteroaralkyl, Cg-Cnaralkenyl, C 8 -Cι 0 heteroaralkenyl, OR T6C , OC(O)R T4C , SR T4C , SO 2 R T9C or SO 3 R T5C ; each of R T2C , R T3C and R T4C is independently hydrogen, Cι-Cι 2 alkyl, C-dheteroalkyl, C 3 -C 12 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cnhetero- cycloalkenyl, C 6 -, Cι 0 - or Cι 4 aryl, C 2 -C 9 heteroaryl, C 7 -Cn aralkyi, C 6 -C 0 heteroaralkyl, Cg-daralkenyl or C 8 -Cι 0 heteroaralkenyl; each of R T5C , R πc and R T8C is independently hydrogen, M y , Cι-Cι 2 alkyl, Ci-Cnheteroalkyl, C 3 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cn heterocycloalkyl, C 2 -Cnhetero- cycloalkenyl, C 6 -, Cι 0 - or Cι aryl, C 2 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, Cg-Ci aralkenyl or C B -Cι 0 heteroaralkenyl; R T6C is hydrogen, d-C^alkyl, Ci-Cnheteroalkyl, C 3 -C 2 alkenyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -Cn heterocycloalkyl, C 2 -Cn heterocycloalkenyl, C 6 -, Cι 0 - or Cι aryl, C 2 -C 9 heteroaryl, C 7 -Cn aralkyi, C 6 -Cι 0 heteroaralkyl, Cg-Cnaralkenyl, C 8 -Cι 0 heteroaralkenyl, SO 3 R T5C , POaR^R 780 , C(O)OR T9C , C(S)NR T2C R T3C or C(O)NR T2C R T3C ; and R is C,-Cι 2 alkyl, Ci-Cnheteroalkyl, C 3 -Cι 2 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -C 12 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cn heterocycloalkenyl, C 6 -, Cι 0 - or C 14 aryl, C 2 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, Cg-Cnaralkenyl or C 8 -Cι 0 heteroaralkenyl; wherein the substituent is selected from the group consisting of OH, halogen, NH 2 , C(O)R sZ , C(O)OR 5 ', OC(O)R s4 , nitro, cyano, SO 3 H, OSO 3 H, SO 3 M y , OSO 3 M y , NR 0 SO 3 M y , C,-d 2 alkyl, C 2 -C, 2 alkenyl, Cι-Cι 2 alkoxy, C 3 -C 12 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -Cn heterocycloalkenyl, C 6 -C 10 aryl, C 6 -Cι 0 aryloxy, C 5 -C 9 heteroaryl, C 5 -C 9 heteroaryloxy, C 7 -C,ιaralkyl, C 7 -Cn aralkyloxy, C 6 -Cι 0 heteroaralkyl, C 8 -Cnaralkenyl, C 7 -Cι 0 heteroaralkenyl, primary amino, secondary amino, sulfonyl, sulfonamido, carbamido, carbamate, sulfonhydr- azido, carbhydrazido, carbohydroxamic acid and aminocarbonylamido, where R s1 is hydrogen, M y , Cι-Cι 2 alkyl, C 2 -C 12 alkenyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 -C, 0 aryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl or C 6 -Cι 0 heteroaralkyl, R 54 is hydrogen, Cι-C 12 alkyl, C 2 -C 12 alkenyl, C 3 -Cι 2 cycloalkyl, C 2 -Cnheterocycloalkyl, C 6 -Cιoaryl, Cs-Cgheteroaryl, C 7 -Cιιaralkyl or C 6 -Cι 0 heteroaralkyl, and R s2 and R 20 are hydrogen, d-C^alkyl, C 2 -C 12 alkenyl, C 3 -Cι 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnheterocycloalkyl, C 2 -C -hetero- cycloalkenyl, C 6 -Cιoaryl, C 5 -Cgheteroaryl, C Cnaralkyl, C 6 -C 10 heteroaralkyl, C 8 -Cn-aralkenyl or C 7 -Cιoheteroaralkenyl, and alkyl, alkenyl, alkoxy, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, aryloxy, heteroaryl, heteroaryloxy, aralkyi, aralkyloxy, heteroaralkyi, aralkenyl and heteroaralkenyl in turn are unsubstituted or substituted by one of the abovementioned substituents; and y is 1 and M is a monovalent metal or y is 1/2 and M is a divalent metal; and a derivative thereof wherein at least one OH is substituted with SO 3 R T5C , C(O)R T9C , C(O)OR T9C , C(S)NR T2C R T3C , C(O)NR T2C R T3C , Cι-C, 2 alkyl, C 3 -Cι 2 al- kenyl, C 3 -C 12 cycloalkyl, C 3 -Cι 2 cycloalkenyl, Ci-Cnheteroalkyl, C 2 -Cnheterocycloalkyl, C 2 -Cιιheterocycloalkenyl, C 6 -, C )0 - or Cι aryl, C 2 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 hetero- aralkyl, C 9 -Cnaralkenyl or C 8 -Cι 0 heteroaralkenyl; in free form or in salt form. 2. The compound according to claim 1 , wherein R 2 is hydrogen, unsubstituted or substituted C,-C 6 alkyl, wherein the substituent is selected from C(O)OH, -C(O)ONa, -C(O)OK, -OH, -C(O)-NR B " R 9" and -SO 2 -NR 8" R 9" , in which R 8" is H, C,-C 4 alkyl, C 2 -C 4 hydroxyalkyl, phenyl or benzyl, and R 9 independently has the meaning of R 8 , or R 8 and R 9 are together tetramethylene, pentamethylene or -CH 2 CH 2 -O-CH 2 CH 2 -. 3. The compound according to claim 1 having the formula IA, IB or IC wherein X, R 1 , R 2 , R T1 , R T2 , R B5 and R 5 are as defined in claim 1 and R 3 is hydrogen or M y ; and R 4 is Cι-C 12 alkyl, C 2 -C 12 alkenyl, C 3 -C 2 cycloalkyl, C 3 -Cι 2 cycloalkenyl, C 2 -Cnhetero- cycloalkyl, C 2 -Cnheterocycloalkenyl, C 6 -Cιoaryl, C 5 -C 9 heteroaryl, C 7 -Cnaralkyl, C 6 -Cι 0 heteroaralkyl, C 8 -Cnaralkenyl or C -Cι 0 heteroaralkenyl, which are unsubstituted or substituted by one or more substituents selected from the group of substituents according to claim 1. 4. A process for the preparation of a compound according to claim 1 wherein the corresponding galactose-GlcNAc-disaccharide or galactose-tetrahydropyran dimer is linked with the corresponding fucose-derivative or the corresponding fucose-GlcNAc-disaccharide or fucose-tetrahydropyran dimer is linked with the corresponding galactose, wherein the groups R 1 , R τ \ X-R T2 , R B5 and/or R 5 are optionally introduced before or after the formation of the dimer or trimer. 5. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use as a pharmaceutical. 6. A method for preventing or treating disorders in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 7. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable diluent or carrier. 8. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the manufacturing of a medicament for use in the method according to claim 6.

Inventors: BAENTELI ROLF, KINZY WILLY, THOMA GEBHARD, BAENTELI, ROLF, KINZY, WILLY, THOMA, GEBHARD
Applicants: BAENTELI ROLF, CIBA GEIGY AG, KINZY WILLY, THOMA GEBHARD, BAENTELI, ROLF, KINZY, WILLY, NOVARTIS AG, THOMA, GEBHARD
Application year: 1997
Main classification: C07H3
IPC codes: A61K31, A61P29, A61P43, C07H3, C07H13, C07H15, C07H17